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ABSTRACT 
Induction of DNA damage by topical application of spermicides and microbicides: 
consequences to viral pathogenesis 
Joseph Owusu-Boateng 
Mary K. Howett, Ph.D. 
 
 
 
 
Among women’s sexual health threats are disproportionate susceptibility to sexually 
transmitted disease (STD) and the possible lubrication of cervical barriers such as 
male condoms with nonoxynol-9 (N-9), which may enhance human 
immunodeficiency type 1 (HIV-1) transmission. Strategies for prevention of STD are 
insufficient to combat HIV-1 and other STD infections. Existing intervention 
strategies have deficiencies. Condoms/abstinence does not guarantee protection. 
Gardasil®, Human papillomavirus (HPV) vaccine does not cover all strains. STD has 
a higher societal cost. In the United States, STD treatment including HPV is over $8.4 
billion annually. Topical microbicides therefore as our “new hope” are needed to fill 
this “gap” in order to control STD morbidity and mortality. Development of a 
female-friendly spermicide/microbicide is a priority with its ability to replace N-9 as 
a spermicide of choice in male latex condoms and perhaps with product expansion 
as a spermicide/microbicide personal lubricant. We compared the known N-9 used 
over 50 years for its contraceptive role with an alkyl sulfate, sodium dedocyl sulfate 
(SDS); a candidate microbicide. These two compounds disrupt cellular membranes, 
but SDS has additional property of chaotropism and protein denaturant. SDS also 
inactivates non-enveloped viruses such as HPV and other enveloped viruses in vitro 
 x 
and has broad antiviral and antibacterial activities than N-9. We examined the DNA 
damaging levels and recovery effects of the tested compounds using the alkaline 
comet assay. Moreover, we tested the hypothesis that N-9 associated DNA damage 
may facilitate HPV integration into the host genome and therefore increase the risk 
of cervical cancer. We assessed HPV DNA integration by determining viral 
sequences in the host genome using PCR and integrated HPV-16 PCR. 0.01%  (0.162 
mM) N-9 causes relatively more DNA damage than 0.01%  (0.162 mM) SDS in HeLa 
cells as evidenced by the comet assay. As a new comparator for topical 
spermicides/microbicides, measuring DNA damage and repair is a novel way to 
evaluate these compounds. Evaluating formulations therefore under the same 
testing conditions can help to distinguish between potential compounds likely to 
show promise as safe microbicides. SDS may prove safer than N-9 as a spermicide or 
microbicide. 
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1. INTRODUCTION 
 
1.1. Topical Spermicides and Microbicides 
 
“[We] need to accelerate research on new HIV prevention tools – 
especially microbicides – to empower women” 
 
- Bill Gates 
Keynote Address 
XVI International AIDS Conference 
Toronto 2006 
 
 
‘‘New prevention strategies such as microbicides are desperately needed by women in 
developing countries and these commitments take us one step closer to making them a 
reality.’’ 
 
- Dr. Zeda Rosenberg, CEO 
International Partnership for Microbicides 
World AIDS Day, 2005 
 
 
‘‘ … And we must ensure they have full access to the practical options that can protect them 
from HIV- including microbicides, as they become available.’’ 
 
- UN Secretary-General Kofi Annan 
XV International AIDS Conference 
Bangkok 2004 
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1.1.1. Overview of STD prevention strategies 
New and effective strategies are needed to combat the worldwide increase in 
the acquisition of sexually transmitted disease (STD), the development of female-
controlled topical microbicides that would be less toxic and ultimately safe upon 
frequent use and effective against a broad range of sexually transmitted pathogens 
has been identified as a high priority1,2. This strategy could be further beneficial by 
making protection against STD a female prerogative. Continued work is urgently 
required to develop economical, safe and effective topical microbicides. 
The global spread of HIV-1 via heterosexual transmission, the predominant 
route of transmission in developing settings highlighted the necessity for extra 
measures to combat the transmission of human immunodeficiency virus type 1 
(HIV-1), including the development and access to broad-spectrum and efficacious 
vaginal microbicides for use during heterosexual intercourse3.   
Since the emergence of HIV/AIDS in the early 1980s, about 50% of the 42 
million people now living with the pandemic worldwide are women4. The 
“feminization” of the disease mainly determined by social, economic, and biological 
factors deserve urgent attention mainly for the adolescent female population. The 
pandemic is also having a disproportionate impact on communities of color. 
Acquired immune-deficiency syndrome (AIDS) is the leading cause of death among 
young African-American women aged 25-345,6. Due to lack of an effective curative 
anti-HIV therapy or vaccine, efforts are targeted towards developing topical 
formulations of anti-HIV agents or microbicides to control mucosal and or perinatal 
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HIV-1 transmission. An ideal microbicide would be women-controlled with broad 
spectrum antibacterial and virucidal activities including HIV-1, in addition to other 
STD pathogens such as human papillomavirus (HPV) and herpes simplex virus type 
1 (HSV-1) and type 2 HSV-2), inexpensive, available over the counter and capable of 
providing dual protection from both sexually transmitted infections (STIs) and 
unintended pregnancy. In a perfect product, topical microbicdes would be effective 
against STD pathogens with minimal effects on the female genital tract, have a 
broad-spectrum and inexpensive, female-controlled, long duration of effect, discreet 
use that is no color, taste or odor; at easy to use and store7-9 10. Besides these product 
acceptability characteristics, during design other factors to consider include 
provision of protection if used consistently, should show negligible absorption, 
availability and continuity of supply7 and to benefit men to be bi-directional, that is, 
capable of disabling HIV-1 in vaginal secretions in addition to semen. The use of an 
ideal microbicide should not result in enhanced migration of inflammatory cells into 
the vaginal tract or in the activation of resident innate immune cells and not alter or 
interfere with the natural protective mechanisms of the genital tract. Topical 
microbicides could provide protection by killing or inactivating infectious 
pathogens, blocking attachment to target cells and entry of infectious pathogens and 
enhancing vaginal defense mechanisms8. Thus, ideally, potential topical 
microbicides should be capable of attacking pathogens and other infectious 
organisms from different angles. In addition, a contraceptive topical microbicide 
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with or without spermicidal activity could help prevent unintended pregnancies 
globally9. 
Although women are able to control their fertility through a variety of 
contraceptive methods, the condom is currently the only option available to women 
to protect themselves against infections. When used consistently and properly, 
application of condoms for contraception and disease control are still the most 
effective protection against STD11. Even though condom usage among other safe 
sexual practices can reduce the risk of STD transmission, cultural factors and gender 
inequality issues deter the appropriateness and consistency of the use of condoms 
and therefore limit their effectiveness12. Thus, latex condoms represent an effective 
barrier against sexually transmitted pathogens, but unfortunately, their use is not 
generalized. 
The female condom is the first woman-initiated barrier method that protects 
against HIV-1 and STIs as well as pregnancy. It gives women options to choose. 
Since its introduction in 1992, the female condom has become available in over 70 
countries. In addition to benefiting women's sexual and reproductive health, the 
female condom contributes to women's sense of empowerment, especially if 
supported by education and informational activities. Unfortunately, access to the 
female condom has been somewhat limited and uptake of it has been negatively 
affected by a number of factors including cost, which remains the major barrier to 
access. The public sector must play a role in making female condoms widely 
available and affordable, as well as generating awareness of their benefits. 
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Guaranteeing accessibility requires a sustained commitment to providing ongoing 
support for users and providers, through informational materials, promotional 
messages and training. As a device worn by the woman, not the man, the female 
condom remains the only available HIV-1 prevention method under a women’s 
direct control. These female condoms give women more power and responsibility 
relating to safer sex and contraception. However, like the male condom; social or 
economic power remains necessary to insist on condom use and fidelity. The risk of 
being a spouse, or income from a paid liaison, still makes it difficult for women to 
negotiate safer sex even in this instance. Although, it is a vital part of the range of 
prevention options for women; female condoms are not popular.  
Antibiotic treatment of bacterial STIs may be effective at terminating the 
infection. However, curative treatments for HPV or HSV-2 or HIV-1 infections do 
not exist. Moreover, the majority of vaccines and pharmaco-therapies are 
undergoing clinical trials and even if effective in decreasing one’s burden, they do 
not remove latent virus. Most of these treatments are also economically inaccessible 
to the worldwide community most notably in developing settings13.  Gardasil®, an 
HPV vaccine marketed by Merck and company with FDA approval contains the coat 
proteins of low risk (types 6 and 11) and high risk (types16 and 18) that are 
associated with genital warts (benign, vaginal and cervical intraepithelial 
neoplasias) and cervical cancer. This vaccine is targeted for pre-sexually active 
females (ages 9-26), i.e., prevention and does not cure existing infections. Cervarix™, 
the Glaxo SmithKline (GSK) cervical cancer vaccine for prophalytic purposes and 
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available for commercial use in Europe only also offers protection against 
precancerous lesions caused by HPV-16 and HPV-18 alone in pre-sexually active 
females. These two vaccines do not protect against other high-risk types of HPV. 
Gardasil®, vaccine has demonstrated the longest duration of more than five years 
type-specific protection seen in any cervical cancer vaccine trial reported to date. 
Life-long protection and re-vaccination strategies are less clear. Moreover, 
recognition of the empty niche by other low or high HPV types following 
elimination of HPV-6, HPV-11, HPV-16 and HPV-18 from the demographic may 
occur. In addition these vaccines, notably Gardasil® are expensive, denying U.S. 
women of low socio-income status and women in the developing world access. At 
this point the decision to administer the vaccine remains a personal choice of parents 
and their adolescent girls. 
  With the deficiencies existing in preventive strategies, women are biologically 
at a greater risk for heterosexual transmission14, thus the urgent need to develop 
alternative approaches to decrease transmission across mucosal surfaces, that can 
transform the lives of women and dramatically reduce their vulnerability15. Hence, 
the increasing interest and research efforts in the design of acceptable topical agents, 
collectively termed microbicides, to use vaginally or rectally in order to prevent 
infections such as HPV and other STDs. Microbicides as anti-infective chemicals 
could provide a practical, promising and affordable female-controlled strategy in 
combating the transmission of multiple STDs. 
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1.1.2. Topical microbicides access and use to prevent STD.  
  The World Health Organization (WHO) defines microbicides as compounds 
that can be applied inside the vagina or rectum to protect against STDs16. The 
Alliance for Microbicide Development indicates that the term ‘microbicide’ refers to 
a range of products, potentially in gel, cream, film or suppository form, and include 
sponges or vaginal rings that slowly release the active ingredient over time being 
developed to significantly reduce the transmission of HIV-1 and other sexually-
transmitted infections of viral, bacterial, fungal or protozoan etiology when applied 
topically to genital mucosal surfaces17. Topical microbicides currently under study 
as shown in Figure 1.1 include condom coatings, foams and semi-solid formulations 
such as gels or creams, applied usually at the vagina and/or penis. These are not 
commercially available. Microbicides can be contraceptive or non-contraceptive. 
Microbicides are being developed to supplement existing prevention strategies such 
as condoms and other contraceptives. Microbicides would offer protection by killing 
HIV-1 or preventing HIV-1 from fusion, entering susceptible target cells, in addition 
to dessemination from target cells found in semen or host cells lining the vaginal 
walls. Therefore, candidate microbicides should be able to inactivate STD pathogens 
including HIV-1 and HIV-1 infected cells from different angles. Potential 
applications of microbicides include prevention of STDs and prevention of mother-
to-child-transmission (MTCT) of STD at postruition and inactivation of pathogens in 
human milk10,18,19. Microbicides could be applied in advance of sexual  
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Future formulations 
 
 
Figure 1.1: Topical microbicides. 
They may include gel, cream, film or suppository formulations 
and possible future formulations such as sponges and vaginal 
rings. They are not currently available commercially 
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activity, and without the active involvement or perhaps even the knowledge of the 
spouse20. Several such products are being tested in populations at high risk for these 
infections whilst others are still in the preclinical or clinical pipeline. Table 1.117 
shows the major categories of topical microbicides7-9,15,21-23  currently under study 
and corresponding microbicidal products in development. Besides these 
mechanisms of action, other mechanisms such as multiple mechanisms / 
uncharacterized mechanisms exist. Regarding microbicides and men, microbicides 
may work for rectal use, but the safety and effectiveness of microbicides for rectal 
use must be established separately. N-9, currently used as a spermicide has not only 
been shown to increase risk to female HIV-1 transmission, it has also been shown to 
be legally destructive to rectal epithelium and should not be used in this way. 
 Topical microbicides differ from antibiotics in several distinct aspects. The 
mechanism of microbicides is to kill or decrease the viability of target pathogens to a 
point below the infectious dose prior to infection. However, antibiotics are most 
often used to treat after the establishment of infection. Furthermore, microbicides 
are expected to exert their antimicrobial effects over a very short period of time 
(minutes), while antibiotics are used over days. Drugs used as antibiotics have to kill 
thoroughly over the time course of administration to be effective, and laboratory 
investigations to evaluate microbicides must detect a rapid decrease in microbial 
density following exposure. Although not all microbicides need interaction with the 
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Table 1.1: Mechanisms of action for major microbicide classes.  
Classification of microbicides is based on mechanism of action. 
Majority of microbicides in research and development act through one or  
more mechanisms. Generally, microbicides inactivate or block pathogens. 
 
 
Class  Mechanism of 
Action* 
 
Examples of products 
Surfactants, 
protein 
denaturants 
 
Dissolve lipids 
and may denature 
proteins 
 
Alkyl sulfates (SDS) 
 
High molecular 
weight charged 
polymers or 
sulfated 
polysaccharides 
Blocking agents / 
inhibit adsorption 
by binding to 
virus and cell 
proteins 
 
Dextran sulfate 
Acid buffers Maintenance of 
vaginal acidic pH 
 
BufferGel™, ACIDFORM gel, 
Lactobacilli 
Entry / fusion 
inhibitors 
Inhibition of virus 
entry and/or 
envelope fusion 
 
Receptor blockers, CCR5 
inhibitors e.g. RANTES analogues 
(PSC-RANTES), Cyanovirin-N 
 
Replication 
inhibitors 
Adsorption HIV-1 
reverse 
transcriptase   
 
Tenofovir 
Polybiguanides Dual co-receptor 
inhibitor 
 
Polyethylene hexamethylene 
biguanide (PEHMB) 
 
 
*Other mechanisms = multiple mechanisms / uncharacterized mechanisms  
 
Halted trials: N-9, Savvy™ (C31G), Cellulose sulfate (CS), and Carraguard® 
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vaginal epithelium to elicit protection, they will directly contact the epithelium and 
interact with it in a manner dependent on the physicochemical properties of the 
microbicides. This raises issues of safety, efficacy, systemic absorption and 
formulation. 
Classification of microbicides is based on mechanism of action. Most 
microbicides under development act through one or more of these mechanisms: 1) 
Killing or inactivating pathogens by breaking down the surface or envelope of the 
pathogen, 2) inhibiting adsorption of pathogens by creating a physical barrier or 
inhibiting entry, 3) fusion of pathogens, 4) others may boost the vagina’s natural 
defenses and inhibit viral replication. Based on the decision that N-9 cannot be a 
microbicidal agent, further microbicide research must be encouraged directed 
toward the development of other microbicidal agents with broader activity and 
lower toxicity. For review, see the Alliance for Microbicide Development website 
(www.microbicide.org). For the purposes of this project, our focus is on possible 
DNA damage by N-9 and comparative studies ith two additional candidate 
microbicides, SDS, and Carraguard™. This study represents a new method to assess 
microbicide safety and raises epeculations about the effects this damage may have 
on cervical and vagina cells harboring latent viruses.   
The microbicide pipeline involves the stages of development of a candidate 
product, from early discovery, preclinical testing to final effectiveness studies and 
approval by the Food and Drug Administration (FDA). Currently, (as at May 2008) 
there are over 40 confirmed products in preclinical testing and 12 microbicide 
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candidates in various stages of clinical development. For review, see Microbicide 
Research and Development Database (MRDD). Combining 2 or more microbicides 
to produce an additive or synergestic effect e.g. BufferGel & Pro 2000/5 is also being 
considered.  
Even though the clinical development of microbicides has advanced 
dramatically in the last few years, there are a number of challenges in undertaking 
these microbicide clinical trials.  Among the obstacles with product development 
that could potentially undermine investigator’s ability to show whether these 
products truly work or not are toxicity, irritation and inflammatory processes 
causing DNA damage. These toxicities may increase chances of HPV-induced 
cervical cancer and also increases risk of HIV-1 transmission through lymphocytes 
recruitment as target cells. Effects on HSV-2 reactivation are unknown. Others 
include lack of biological markers of activity or protection, lack of a truly inert 
“placebo” with equal viscosity and the ethical need to promote condoms making 
effectiveness trials large and difficult.  
 
1.1.3. Acceptability of microbicides and condom use  
Based on a U.S. representative survey, growing evidence shows that 
individual women within and across cultures stated different preferences for 
products and other characteristics, safety and effectiveness regarded as most 
important with primary concerns between women and men being long-term side 
effects and effect on sexual pleasure. For review see24. 
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Microbicides could be potentially available for use as early as 2010 and through a 
mathematical model, likely to be about 60% effective against HIV-1 infection25. In 
reality, through a mathematical model if even a small proportion of women in lower 
income countries used a 60% efficacious microbicide in half the sexual encounters 
where condoms are not used, 2.5 million HIV infections could be averted over 3 
years26. Although condoms are not 100% effective, they provide the optimum form 
of protection for sexually-active partners, using a topical microbicide will be much 
safer than nothing for women with lack of condoms or usage restrictions. Because 
some sexual partners, the contraceptive effect of condoms is a major deterrent for 
use, developing both contraceptive and non-contraceptive microbicides is indicated. 
Hence, microbides are currently being promoted as an adjunct or “back-up” to 
condoms, not as a replacement.  
Thus, proven safe and effective, topical microbicides may be used in 
combination with other cervical barrier methods such as condom, diaphragm or 
cervical cap. Moreover, future microbicides may focus on combination of products 
capable of inactivating HIV-1 and other STD pathogens at multiple steps in their life 
cycle to increase efficacy, limit cross-resistance, in addition to minimizing 
microbicide-induced host toxicity. 
 
1.1.4. Evaluating the safety of vaginal microbicides 
Before they can be licensed for consumers, candidate microbicides must go 
through rigorous and a series of tests to evaluate their safety. Product developers 
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define safety as a person’s ability to use a product without negative impact on the 
body. “Safety” refers to the absence of significant adverse events related to 
microbicides use in the study population. “Safety” does NOT mean “keeping 
participants safe from infection.” Any new drug, including microbicides have to be 
methodically researched in standardized laboratory tests before human testing. 
Evaluation of safety involves pre-testing i.e. both non-clinical and the clinical 
research.  
The pre-testing comprises the discovery of the product and laboratory testing. 
Pre-clinical studies include in vitro and in vivo testings. The main purpose of the pre-
clinical methods of evaluation is to ensure that the benefits outweigh the risks before 
a compound goes to clinical trials. Extensive studies are conducted utilizing 
microbiological, pharmacological, toxicological and chemical methods27. Successful 
pre-clinical trials are a requirement for clinical trials. Thus non-human data are 
needed demonstrating that the product under study has no marked toxicities and is 
potentially beneficial to end-users. Only compounds considered to be safe in 
preclinical tests are further investigated in clinical trials with human volunteers. All 
drugs, including microbicidal products, go through evaluation steps as shown in  
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Table 1.2: The product pipeline. 
Preclinical studies include in vitro testing and tests conducted in animals. Following 
approval for human trials, a product goes through a series of phases. Clinical trials 
involve 3 phases. Two-phase 3 trials may be necessary before a product is proven 
effective. The whole process of microbicide approval takes about a decade. 
 
 
Stages of microbicide development 
 
 
Preclinical 
Evaluation 
 
 
Clinical Trials 
 
Laboratory testing 
 
 
 
Phase 1 
 
Phase 2 
 
Phase 3 
 
Purpose 
 
 
Safety 
 
Safety/Efficacy 
 
Efficacy 
 
Duration 
 
 
1-6 months 
 
Up to 2 years 
 
2-4 years 
 
Tests for toxicity 
and antiretroviral 
activity in cell 
cultures, tissue 
explants, and 
animals  
Subjects 
 
25-40 people 
 
200-400 people 
 
3,000-10,000 
people 
 
 
 
 
Adapted from: Global Campaign for Microbicides 
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1.1.5. Nonoxynol-9 
Nonoxynol-9 (N-9) (C33H60O10, CAS #26571-11-9, MW 617), a surfactant and a 
proven spermicide had been used worldwide for over 30 years for contraception. It 
is a non-ionic detergent containing an uncharged hydrophilic head group. It can 
disaggregate cellular and viral membranes. Figure 1.2 shows the structural formula 
of N-9. For ideal use of detergents  (also known as surfactants because they decrease 
the surface tension of water), knowledge about how and the quantity needed to 
interact with the integral membrane proteins and membrane liquid is necessary. For 
review, see Tanford28,29.  
 
                                                 
 
 
(Nonylphenoxypolyethoxyethanol) 
 
www.commons.wikipedia.org 
Figure 1.2: Structure of nonoxynol-9 (N-9)                                               
Molecular formula is C33H60O10 and molecular weight is 616.8 g/mol. N-9 is a non-
ionic surfactant and contains an uncharged hydrophilic head group. It is used 
mostly in contraceptives including foams, condoms and cervical barriers for its 
spermicidal properties. 
 
 
Detergent partitioning in the membranes go before cooperative binding and 
solubilization, facilitated by exposure to detergent micelles. Critical micelle 
 17 
concentration (CMC) is the concentration at which surfactants begin to form micelles 
that contain several detergent molecules. CMC also defined as the lowest 
concentration above which monomers cluster to form micelles is the maximum 
chemical potential or concentration within reach of the monomer. The CMC of 
surfactant can be determined using the three common methods, namely dye 
solubilization, light scattering and surface tension. The first potential microbicidal 
product to be clinically evaluated contained N-9. Initially, N-9 received much 
attention based primarily on its ability to disrupt lipid membranes or envelopes of 
bacterial and viral pathogens such as inactivating HIV-1 in vitro30 and was the first 
candidate microbicide to reach phase III clinical trials. N-9 interacts with and 
disrupts lipids on cell membranes or envelopes of bacterial and viral pathogens31-33. 
N-9 has been tested for microbicidal use. Though N-9 has in vitro activity against 
more than a few STD pathogens, including HIV-134,35 it has no activity against non-
enveloped viruses for example HPV36. Moreover, in vivo effectiveness of N-9 is not 
well understood, with adverse effects that may increase the risk of HIV-1 
transmission during sexual intercourse. To date, N-9 has received approval from the 
FDA for use as a vaginal spermicide only. WHO statement recommends for topical 
therapeutic considerations, and suggests that N-9 should not be used rectally under 
any circumstance16. There is little evidence that N-9 is metabolized7.  About 18 
spermicidal products contain N-9 in different formulations (gels, foams, creams, 
vaginal suppositories and films), each with 50-150 mg of N-916. The concentration of 
N-9 in the various contraceptive products varies widely such as from 1% to 4% in 
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gels and creams and 28% in films. Most preparations may be used alone, or for more 
effective contraceptive results, with concurrent use of a female mechanical method / 
barrier (e.g. diaphragm)16,37. Vaginal exposure of mice to N-9 recruits lymphocytes 
to the cervix30. Likewise, in women vaginal use of N-9 caused increased amounts of 
lymphocytes in cervical and vaginal epithelium16,37 which in turn may enhance HIV 
transmission due to the increased number of target cells38. Interest in the use of N-9 
as a topical microbicide was also diminished due to reports of cellular epithelial 
disruptions and erosions, inflammatory responses21,39,40 and increased rates of 
acquisition of STD including HIV and HPV following repeated use40,41. Previous 
studies by Catalone and colleagues indicated diffuse lymphocyte infiltration in the 
mouse cervix following 1% N-9 exposure at 10 min up to 2h30(data not shown). Kish 
demonstrated that single application of the 1% N-9 up to 24h in mice could cause 
intense inflammation with leukocytes, infiltrating the vaginal lumen within four 
hours21, 42 as shown in Figure 1.3. However, thinning of the epithelium occurred 
with continuous exposure (data not shown). This inflammatory response may likely 
induce oxidative events leading to DNA damage. This DNA damage may in turn 
favor HPV integration or other virus related events in the cervix or vagina.  
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Figure 1.4 shows the degree of epithelial disruption and lymphocyte infiltration at 
the mouse cervix following N-9 administration30. A truly effective vaginal 
microbicide would reduce the susceptibility of women to STDs, including infection 
 
 
Figure 1.3: 1% N-9 single treatment causes cervical epithelial 
toxicity in Swiss Webster mice. 
The mice epithelium demonstrated initial epithelial disruption after 
a single application of 1% N-9. Saline control = Panel A (Negative 
control), Tissues from 1% N-9-treated mice were harvested 
immediately post-application (Panel B), 2 hours (Panel C), 4 hours 
(Panel D) and 8 hours (Panel E). Data demonstrate that a single 
application of 1% N-9 can disrupt the epithelial layer out to 4 hours 
post-application. Regions of mucosal damage to point of exposing 
lamina propria (arrows, Panels C and D). Mucosa tissue integrity 
restored approximately 8 hours post-application.  
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with HIV-1.  Research has determined that N-9 offers no protection against STD 
transmission as it increase the risk of infection due to mucosal inflammatory 
damage43,44 and also causes vaginal inflammation and ulceration which increase 
HIV-1 in-vivo transmission45. Because treatment with N-9 is known to increase 
inflammation, we hypothesized that it may generate reactive oxygen species (ROS) 
and enhance DNA damage21. The squamous cells of genital epithelium and the 
keratin serve as a barrier to viral infection12,46. When used repeatedly, N-9 
containing products may increase the risk of HIV-1 transmission through epithelial 
disruptions47 and also increased the risk of genital lesions48. Higher frequency use of 
N-9 was linked with higher incidence of epithelial disruption in women7.      
Because N-9 mostly works to disrupt the phospholipids membranes of mouse 
epithelial cells, nonspecific damage to vaginal epithelial cells, uterine, and cervical 
tissue may occur. Recent studies have shown that intravaginal application of 1% N-9 
or Conceptrol gel (containing 4% N-9) resulted in disruption of the cervical 
epithelium and recruitment of inflammatory cells to the vagina mucosa21,30. Vaginal 
irritation studies have proved that epithelial disruption is related to the frequency of 
product use particularly for birth control, with minimal concentration (52-150mg) 
inducing little or no disruption when applied once a day or less11,47,49,50. 
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Figure 1.4: 1% N-9 treatment causes substantial lymphocyte infiltration in the 
cervix of Swiss Webster mice. 
Mice inoculated with 60 µl 1% N-9 intravaginally. Tissue sections stained with H&E 
(morphology) and anti-CD45 (IHC). Cervical epithelial tissues severely disrupted at 
4 and 8 h post-application, experienced repair by 24 h post-exposure. Regions of 
epithelial disruption (arrowheads, H&E) and Regions of intense CD45-positive cell 
staining (arrows, CD45). 
 
 
In the studies, not all women who were exposed to N-9 had the symptoms of 
vaginal irritation, however they had epithelial disruption or inflammation, as 
observed by colposcopy. In a similar manner, a woman could have lesions or 
disruption but not experience symptoms of vaginal irritation51. Untreated women 
demonstrated no toxicity effects. 
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1.1.6. Alkyl sulfate microbicides (Sodium dodecyl sulfate)  
Sodium dodecyl sulfate (SDS) (C12H26O4SNa CAS #151-21-3, MW 289), is the 
prototype of alkyl sulfates. SDS is an ionic detergent and contains negatively 
charged sulfate groups. Figure 1.5 shows the structural formula of SDS. The dual 
polarity of SDS allows it to solubilize proteins by imitating their structure. It also 
reduces surface tension of molecules as a surfactant and  denaturation of proteins as 
it binds tightly with the protein amino acids52,53, Kish and Howett, unpublished 
observations) thereby denaturing secondary and non–disulfide–linked tertiary 
structures, and applying a negative charge to each protein in proportion to its mass. 
SDS interacts with the protein in Ca2+-ATPase membranes not only at high, but also 
at low detergent concentrations, prior to denaturation of the protein. Moreover, such 
detergents with strongly hydrophobic heads only very slowly solubilize liposomal 
membranes and do not result in liposomal fusion54,55.  
  SDS is effective at very low concentrations compared with many other agents 
with protein denaturing potency. These properties allow 0.1% SDS (in 10 min at 37 
0C) to inactivate in vitro enveloped viruses (e.g., HIV-1 and HSV-2), non-enveloped 
viruses (e.g., bovine papillomavirus and HPV), and bacteria (e.g. Escherichia coli, 
Staphylococcus aureus, Chlamydia trachomatis and Neisseria gonorrhoeae) (Hartmann 
and Howett, unpublished observations)7,51,56.  
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(Sodium dodecyl sulfate) 
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Also called sodium lauryl sulfate, it is a prototype of the alkyl sulfates. The 
molecular formula is NaC12H25SO4 and the molecular weight 288.4 g/mol. SDS is an 
ionic surfactant and an amphipathic molecule with 12-carbon hydrophilic tail and a 
negatively charged sulfate group. SDS is also a chaotropic agent that dissociates and 
denatures protein on membrane by binding tightly with the protein amino acids. As 
a synthetic detergent, SDS associates with water through the polar regions and trap 
oil and grease through interaction with the hydrophobic tails. SDS is a common 
laboratory purity reagent. 
 
 
 
SDS’s in vitro inactivation of HPV, HSV-2 and HIV-1 was confirmed by Piret and 
colleagues57. The non-ionic detergent N-9 does not inactivate HPV because of the 
protein viral coat7 and the failure of N-9 to denature proteins..   
SDS, commonly used in research applications is found in personal hygiene 
products such as toothpaste and shampoo. Two vaginal formulations in which SDS 
is used as an excipient have also been identified. One of these preparatory products 
has a daily dose formulation and exhibits virucidal activity against HPV and HSV-
27. SDS is highly metabolized and has been categorized by the United Nations 
Environmental Program as readily ‘‘biodegradable’’7 and in FDA’s Generally 
Figure 1.5: Structure of Sodium dodecyl sulfate (SDS).  
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recognized as safe (GRAS) list58. Humans also possess sulfatases to remove the 
sulfate for degradation of SDS7.  Nevertheless, topical use of SDS may not 
significantly increase blood levels of this chemical7.  
The use of SDS as a potential vaginal topical microbicide has been 
demonstrated in studies by51,56,59 and others34. In vitro studies identified that SDS is 
relatively less toxic than N-9, by as much as 30-100 fold depending on the 
assay51,56,60(data not shown). Assays on keratinized tissues, or mice columnar 
epithelium shows even higher lack of SDS sensitivity. In such assays, 1% SDS in 
aqueous solution yielded similar results to isotonic buffer placebo in a 10 day, once 
daily exposure, rabbit vaginal irritation assay7. SDS could then be considered as a 
candidate microbicide for formulation and testing with humans56. 
 
1.2. DNA Damage and Repair 
1.2.1. DNA damage overview 
All cells depend on DNA to transmit genetic information. DNA damage 
could be defined as drug- or radiation-induced injuries in DNA that introduce 
deviations from its normal double-helical conformation. These changes include 
structural distortions, interfering with replication and or transcription, in addition to 
point mutations that disrupt base pairs and may exert damaging effects on future 
generations through DNA sequence changes. Minor damages can be often repaired, 
but extensive damage may induce apoptosis61,62.  
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DNA damage, due to environmental factors and normal metabolic processes 
inside the cell, occurs at a rate of 1,000 to 1,000,000 molecular lesions per cell per 
day63. Thus, DNA damaging events such as oxidation, alkylation, deamination, 
depurination and depyrimidation of DNA create ~104 mutagenic DNA base lesions 
per day in each human cell. While this constitutes only 000165% of the human 
genome's approximately 6 billion bases (3 billion base pairs), un-repaired lesions in 
critical genes (such as tumor suppressor genes) can impede a cell's ability to carry 
out its function and appreciably increase the likelihood of tumor formation. Table 
1.3 shows the types and frequency of DNA damage. The vast majority of DNA 
damage affects the primary structure of the double helix; that is, the bases 
themselves are chemically modified. These modifications can in turn disrupt the 
molecules' regular helical structure by introducing non-native chemical bonds or 
bulky adducts that do not fit in the standard double helix. Unlike proteins and RNA, 
DNA usually lacks tertiary structure and therefore damage or disturbance does not 
occur at that level. DNA is, however, supercoiled and wound around "packaging" 
proteins called histones (in eukaryotes), and both superstructures are vulnerable to 
the effects of DNA damage. 
The living cell is constantly exposed to potentially damaging free radical 
species, the origin may either be intracellular, such as those arising from normal 
cellular metabolism, or extracellular produced as a consequence, notably exposure 
to UV light or ionizing radiations.  
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Table 1.3: Types and frequency of DNA damage. 
More than 500,000 DNA damaging events occur per cell per day due to oxidation, 
hydrolysis, alkylation, radiation or toxic chemicals. Single-strand breaks occur 
frequently, but they are repaired rapidly by the cells evolved repair mechanism. 
Double-strand breaks are infrequent, but not easily repaired by the cell. 
 
 
Type of damage 
 
 
Events / cell / 
day 
 
% of total daily 
damage 
Single-strand breaks  
 
120,000 50.9 
N7-MethylGuanine 
 
84,000 35.6 
Depurination 
 
24,000 10.2 
O6-MethylGuanine 
 
3,120 1.3 
Oxidized DNA 
 
2,880 1.2 
Depyrimidation 
 
1,320 0.5 
Cytosine deamination 
 
360 0.2 
Double-strand breaks 
 
9 0.01 
Interstrand cross-links 
 
8 0.01 
 
 
Molecular oxygen is essential but it can cause serious harm to aerobic organisms. 
Oxygen readily abstracts electrons from other molecules in the cell to form reactive 
oxygen species (ROS). This electron reduction leaves donor molecules with unpaired 
electrons, causing them to become reactive radicals64,65. The generation of ROS may 
be both beneficial to cells, performing a function in cellular signaling or harmful, 
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modifying cellular biomolecules in ways which when accumulated have been linked 
with many diseases. Thus, ROS are of particular interest. Cellular targets for 
oxidative modification by ROS include DNA, lipids and proteins, and the order of 
preference for modification is based on factors such as location of ROS generation, 
relative ability of the biomolecules undergoing oxidation producing metal ions. 
DNA has received the utmost attention among the biomolecules subject to oxidative 
modifications. Normal and HPV infected cervical epithelium can be damaged from 
incoming systemic factors such as carcinogens and chemicals. Despite stable 
genomes of all living organisms, cellular genomes are most frequently challenged by 
environmental stress notably chemical and physical agents in the environment such 
as UV and ionizing radiations, bacterial toxins, chemical mutagens including other 
chemicals used in chemotherapy especially in cancers and by biological agents such 
as free radicals or alkylating agents endogenously generated in metabolism, that 
introduce changes of the chemical structure of the DNA66 as well as changes in other 
biochemical pathways. Other possible causes of DNA damage include errors during 
its replication, response to virus or pathogen, development and homeostasis. 
Intracellular reactive metabolites such as ROS and alkylating compounds are 
important inducers of cellular damages65. DNA damage caused by ROS is also called 
oxidative DNA damage and is the most common damage encountered by aerobic 
cells65. Hydrogen peroxide, superoxide anion, nitrous oxide and hydroxyl radical 
are typical examples of ROS66,67. Even though concentration of these highly reactive 
species are kept at sub-toxic levels by the action of specific antioxidants68,69, the level 
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of oxygen free radicals in a cell can be increased by intra or extracellular stimuli, 
leading to oxidation of key cell components in a process described as oxidative 
stress. The toxic DNA lesions produced by these agents could be altered bases, 
missing bases, mismatched bases, deletion or insertion of linked purines and 
pyrimidines, strand breaks and strand cross-links66. The damage to the DNA is 
indicated by the detection of various base modifications, particularly the oxidized 
base 8-oxoguanine (8-oxoG), a product of hydroxylation of guanine at carbon 8 and 
one of the approximately 20 known radiation damage products and assayed in the 
DNA of the rat liver68,69. DNA damage caused by ROS may not be enough to cause 
apoptosis67 and, if left unrepaired, will induce genome instability. This plays an 
important role in the initiation and progression of cancer and in the occurrence of 
other pathological events such as the ageing process and neurological diseases65,66.  
The major types of DNA damage due to endogenous cellular processes and 
by exogenous agents include mismatches of the normal bases due to errors in DNA 
replication, and covalent modifications of the DNA bases due to oxidation, 
alkylation and hydrolysis at various positions, breaks in the DNA backbone due to 
thermal disruption at elevated temperatures such as single-stranded breaks (SSB) 
and double-stranded breaks (DSB). Others are due to chemicals or ionizing radiation 
and cross-links formed between bases arising from covalent linkages. UV damage, 
alkylation/methylation, X-ray damage and oxidative damage are examples of 
induced damage. Spontaneous damage may comprise the loss of a base and 
deamination. 
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1.2.2. Mechanisms of DNA damage 
Free radicals, especially the hydroxyl radical react with organic compounds 
by addition abstraction. This radical adds up to double bonds of heterocyclic DNA 
bases and abstracts a hydrogen atom from the methyl group of thymine and from 
each of the C-H bonds and 2’ –deoxyribose. Additional reactions of thus-formed C- 
or N-centered radicals of DNA bases and C-centered radicals of the sugar moiety 
leads to different final products. 
In DNA base damage, chemical structures are formed when hydroxyl radical 
adds to the double bond of pyrimidines and purines at diffusion-controlled rates, 
whereas in sugar damage; hydroxyl radical abstracts a hydrogen atom from each of 
the carbon atoms of the sugar moiety in DNA at constant rate. A unique reaction of 
the C5’ –centered sugar radical is the addition to the C8-position of the same purine 
nucleoside. Oxygen inhibits product formation due to its diffusion-controlled 
reaction with the C5’ –centered sugar radical before cyclisation. The formation 
mechanism of the DNA-protein cross-link has been proposed to involve the addition 
of the alkyl radical of thymine in DNA to tyrosine in a protein, followed by 
oxidation.   
1.2.3. Cellular responses to DNA damage 
The maintenance of genome integrity and fidelity is essential for the proper 
function and survival of all organisms. Because cellular DNA is under constant 
assault by genotoxic agents (both endogenous and exogenous), nucleotide 
misincorporation during DNA replication, and the intrinsic biochemical instability 
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of the DNA itself, cells are equipped with DNA damage response pathways that 
trigger DNA repair, cell cycle arrest and if necessary apoptosis to eliminate the 
damaged cells70. All eukaryotic cells therefore have evolved a multifaceted response 
to counteract the damaging and harmful effects of DNA damage as shown in Figure 
1.6. Upon sensing DNA damage or errors in replication, cell cycle checkpoints are 
activated to arrest cell cycle progression to allow cells to uptake repair before the 
ensued damage is progressed through the cell cycle after affecting the progeny. 
Besides checkpoint activation, the DNA damage response results in transcriptional 
programs, improving DNA repair pathways and with pronounced damage to the 
DNA, programmed cell death is initiated62. Hence the genetic material is judiciously 
maintained, duplicated and segregated inside the cell, through effective 
coordination of the processes in all of these regulated pathways.  
 
1.2.4. DNA repair overview 
DNA damage causes changes in protein-coding and regulatory sequences, 
leading to diminished cell function, disease and cancer. DNA repair is a complex 
system of interacting bio-molecular processes71. 
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Modified from R&D systems (www.rndsystems.com) 
 
 
 
 
DNA damage is caused by many different sources. The cellular response to damage 
may include activation of a cell cycle checkpoint, induction of transcriptional 
programs, promotion of DNA repair, or when the damage is severe, initiation of 
apoptosis. 
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Figure 1.6: Generation of reactive oxygen species (ROS) by cellular responses to DNA    damage. 
 
 32 
DNA repair encodes a collection of processes by which the cell identifies and 
corrects damage to the DNA molecules encoding its genome. The DNA repair 
process has to be constantly active in order to respond quickly to any damage in the 
DNA structure. The rate of DNA repair is dependent on many factors, including the 
cell type, the age of the cell, and the extracellular environment. A cell with large 
accumulation of DNA damage, or one that no longer effectively repairs damage 
incurred to its DNA may become senescence, which is an irreversible state of  
dormancy, cell suicide or unregulated cell division, leading to formation of tumor 
that is cancerous as shown in Figure 1.7.  
DNA repair is a cellular mechanism that corrects damage to DNA before it 
can progress. Thus, to combat attack from ROS, and other free radicals, living cells 
have acquired a number of defenses. Although the fidelity of DNA replication is 
very high, errors of mis-incorporation do occur and organisms have evolved a 
number of means of DNA repair. These evolved mechanisms of DNA repair are 
efficient and specific. Around 5% of the genes of these cells are devoted to encoding 
DNA repair and DNA damage response proteins. The focus of DNA repair and 
damage is in protecting the integrity of the genome and thus the cell’s normal 
functioning. Maintenance of genome stability therefore is critical to organisms as 
DNA damage is a serious threat to survival; genome alterations have a fundamental 
role in initiation of tumorigenesis in higher eukaryotes. 
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Figure 1.7: DNA repair rate. 
Unrepaired DNA could progress as a mutation or chromosomal aberration leading 
to deleterious results such as cell death, cancer or age-related disease. Mutagenic 
and cytotoxic potential of DNA lesions is based on the degree of initial DNA 
damage and the ability of the cell to execute DNA repair. Minor damages can be 
often repaired, but extensive damage may induce apoptosis. 
 
 
 
 
 
 
Modified from Prometheus 2004 
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1.2.5. DNA repair mechanisms 
Because the types of damage to DNA are so diverse, the mechanisms and 
molecular pathways monitoring and repairing DNA damage are complex. 
Irrespective of the complexity in types of DNA damage, DNA maintenance and 
repair pathways are very well conserved, from single-celled microorganisms such as 
yeasts, to plants and to humans. Thus yeast and plant genomes encode the same 
general DNA repair pathways present in humans. 
In the eukaryotes, mammalian cells are the majority. Important non-
mammalian model systems include yeast, C. elegans (nematode), Drosophilia 
(fruitfly), Xenopus (amphibian), and plants. Yeast i.e., Saccharomyces cerevisiae and 
higher eukaryotes like humans are two extreme members of the eukaryotic 
kingdom. More than 70 human genes are directly involved in the major pathways of 
DNA repair. The nucleotide excision repair (NER) system, transcription-repair 
coupling components and the many regulatory proteins distinguish the eukaryotic 
repair system from bacterial ones. The methods in this thesis focus on eukaryotic 
model systems that have the potential to make important contributions to cellular 
responses to DNA damage in relation to mutagenesis, carcinogenesis, and the cell 
cycle.  
Damaged or inappropriate bases can be repaired by several mechanisms. The 
two major DNA repair systems include direct chemical reversal of the damage and 
excision repair, in which the damaged base or bases are removed and then replaced 
with the appropriate base(s) in a localized burst of DNA synthesis. This is the most 
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important repair mechanism, where the damaged DNA is recognized, removed 
either as free bases or as nucleotides, and the gap is filled by synthesis of new DNA 
(normal base) using the complementary strand as a template. There are about three 
modes of excision repair, each employing its specialized sets of enzymes, namely 
base excision repair (BER), Nucleotide excision repair (NER) and Mismatch repair 
(MMR). The DNA lesions generated by oxidative DNA damage (e.g., missing bases 
and strand breaks 66 are repaired by specific DNA enzymes71-73. Others may include   
recombination / double-strand base (DSB) repair, homologous recombination (HR), 
non-homologous DNA end-joining, and transcription-coupled repair. 
  In direct reversal, cells are known to eliminate the damage to their DNA by 
chemically reversing it.  This simplest of the human DNA repair pathways do not 
require a template, since the damage to be corrected can only occur in one of the 
four bases. A typical example is photoreactivation. The repair of pyrimidine dimers 
by photoreactivation is common to many eukaryotes (yeast, several species of plants 
and animals). In yeast, photolyases with same mechanism as in bacteria are used. 
However, the process is not universal. Many species (including humans) lack this 
kind of repair mechanism. But humans have other kinds of repair mechanisms that 
directly reverse certain damages.    
In indirect repair, DNA BER is the key system for repairing single-base 
damage or non-bulky damage to bases, spontaneous, alkylation, and oxidative DNA 
in humans67,74,75. An example of oxidative damage removed by BER is 8-oxo-7,8-
dihydroguanine (8-oxoG), common representative biomarker. BER is a multi-step 
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process and complex system of coordinated sequential enzymatic reactions 71,75,76. 
Table 1.4 summarizes the proteins and their functions involved in the excision 
repair pathways. In general, the excision of a base is initiated by DNA glycosylase 
which recognizes and removes damaged bases through hydrolysis68,77. The resulted 
AP site is repaired by apurinic/apyrimidinic (AP) endonuclease. The deoxyribose is 
removed and the single base gap filled by DNA polymerase β (Pol β) and ligation of 
the final nick, by DNA ligase 1 (Lig1)68,78. In humans, BER occurs at a frequency of 
about 100 times a day in each cell. BER and NER are responsible for fixing DNA 
damage by employing analogous biochemical pathways in prokaryotes and 
eukaryotes. NER is perhaps the most flexible of the DNA repair pathways based on 
the diversity of DNA lesions it acts upon. This mechanism removes a whole 
oligonucleotide of 2-30 bases that contains the damage, even though there may be 
only one damaged base to be corrected. NER system is built up of a number of 
distinct helicases and nucleases. In eukaryotes such as S. cerevisiae, the necessary and 
sufficient proteins (helicases) similar to Uvr’s of bacteria are named (‘RAD’ 
representing radiation). These include RAD1, RAD2, RAD3, RAD4, RAD10, RAD14 
and rad25. In higher eukaryotes, human nuclease requires at least 17 polypeptides, 
including XPF, XPG, XPD, XPC, XPA, ERCC1 and XPB; similarly listed for damage 
recognition and removal of oligonucleotide. Thus, the mechanism in eukaryotes is 
very similar to that of prokaryotes, but the proteins share no homology and the 
incision patterns are also different. In eukaryotes, 27-29 nucleotides are removed.  
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Table 1.4: Proteins and their functions involved in DNA repair of Escherichia coli 
(E. coli). 
DNA repair proteins are vital for the prevention of potential DNA mutations 
resulting from DNA damage. Several distinct DNA repair proteins are involved in 
selective repair pathways, some exhibiting narrow substrate specificity (base 
excision) and others characterized by a broad substrate range (nucleotide excision 
repair and mismatch repair). DNA repair mechanisms have evolved and are 
partially conserved in all life (bacteria through mammals). 
 
Repair 
system 
Enzymes/ 
proteins 
Functions 
DNA glycosylase Recognizes Apurinic or Apyrimidation (AP) site 
and removes its base 
AP endonuclease Removes AP site and neighbouring nucleotides 
DNA 
polymerase I 
DNA synthesis using template to fill gap 
Base 
excision 
DNA ligase Seals nick 
 
Uvr-A, Uvr-B, 
Uvr-C 
Recognize and remove damaged nucleotides (e.g. 
Dimer induced by UV light) 
DNA 
polymerase I 
Fills excision gap using template 
Nucleotide 
excision 
DNA ligase Ligation 
 
Dam methylase Identifies the correct base 
MutS, MutL, 
MutH 
MutS recognizes and binds to mismatch base. 
MutL binds to mismatched region. MutH binds 
to GATC sequences. Activated MutH cleaves 
unmethylated strand at the GATC site 
Exonuclease  
(Exonuclease VII 
or RecJ / 
Exonuclease I) 
Removes segment from cleavage site to the 
mismatch (Exo VII or RecJ- degrade single strand 
only in 5’ to 3’ direction / Exo I- degrade single 
strand only in 3’ to 5’ direction) 
DNA helicase II 
Single strand 
binding (SSB) 
proteins 
Assist exonuclease 
DNA 
polymerase III 
Fills gap  
Mismatch 
DNA ligase Seals backbone 
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The human repair system has been reconstituted in vitro with highly purified 
proteins as shown in Table 1.4. 
Briefly, in NER initiated by dual incisions bracketing the lesions with 
hydrolysis of two phosphodiester bonds, damaged bases are removed as 
oligonucleotides and the resulting gaps are filled with polymerase / ligase activity. 
DNA polymerase I fills the excision gap using the unaltered strand as template and 
DNA ligase seals the gap. NER is used for the removal of bulky DNA lesions 
induced by UV-irradiation or by chemicals like cyclobutane pyrimidine dimers 
(CPDs) and 6-4 photoproducts (6-4 PPs) and alkylated bases without error. Though 
inefficient compared to the true mismatch repair system, NER may fix mutation of 
mismatched bases rather than repair.   
Mismatch repair in eukaryotes may be similar to that in E. coli but the 
mechanism to distinguish the template strand from the new strand is not very clear. 
MMR plays an essential role in the correction of replication errors such as base-base 
mismatches and insertion/deletion loops (IDLs) resulting from DNA polymerase 
misincorporation of nucleotides and template slippage, respectively.  There is a 
major expansion of genes encoding MutL and MutS homologs in eukaryotes, with at 
least five or six members found in each eukaryotic genome. Homologs of MutS and 
MutL have been identified in S. cerevisiae, mammals and other eukaryotes, e.g., in 
humans hMSH1 to hMSH5 are homologous to MutS; hMLH1, hPMS1 and hPMS2 
are homologous to MutL.Thus, in humans following recognition and binding to the 
mismatched base pairs by hMSH1 to hMSH5, hMLH1, hPMS1 and hPMS2 further 
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binds to the mismatched region. Then as in E. coli, endonucleases remove the 
segment from cleavage site to the mismatched bases. DNA polymerase III fills the 
gap and ligase seals the backbone. However, the RecJ repair protein in E. coli is not 
conserved in eukaryotes. Mismatch repair systems are central to maintaining 
genome stability in prokaryotes and eukaryotes even though the DNA biosynthesis 
machinery is precise but imperfect. Mismatch repair mechanism repairs base-pairing 
generated by replication or recombination. To repair mismatched bases, the system 
has to distinguish the template strand from the newly synthesized strand containing 
the error. Dam methylase methylate all adenine occurring within (5’)GATC 
sequences in E. coli. MMR proteins are basic in avoiding mutations mostly by 
removing misincorporation errors occurring during DNA replication. Other 
functions of MMR proteins include genetic recombination such as modulating 
meiotic crossover control (repairing mismatches that occur during recombination, 
especially in meiosis), removing 3’ non-homologous tails during double-strand 
repair, and preventing or repressing recombination between divergent sequences. In 
summary as shown in Table 1.4, E. coli mismatch repair is initiated by the protein 
MutS, that recognizes mismatch, and forms complex with MutL and MutH. Then 
activated MutH (an endonuclease) cleaves the unmethylated DNA strand at a GATC 
sequence. Subsequently, the segment from the cleavage site to the mismatch is 
removed by exonuclease (with assistance from helicase II and SSB proteins). DNA 
polymerase III fills the gap and DNA ligase seals the gap. RecJ 5’-3’ exonuclease is 
the only protein that is conserved in most bacteria involved in repair.  In E. coli, the 
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distance between the GATC site and the mismatch could be as long as 1000 base 
pairs. Therefore, mismatch repair is expensive and inefficient. Though missing in 
Mycoplasma, MutL and MutS MMR system components are highly conserved among 
bacteria, whereas MutH is found only in E. coli and Haemophilus influenzae. 
In other repair systems such as recombinational repair; it makes use of the 
undamaged parental strand to undergo recombination shifting the gap to the other 
synthesized DNA molecule. The functional proteins are the RecA/RAD51 
recombinases with mechanisms similar to E. coli. Also homologous recombination is 
a complex repair pathway for DNA strand breaks induced by ionizing radiation that 
occurs in eukaryotes between duplex molecules of identical sequences during 
meiosis. Non-homologous DNA end-joining (NHEJ) is an alternative pathway for 
DSB repair which generally leads to small DNA sequence deletions. Since NHEJ is 
not guided by a DNA template, it can be error-prone. These pathways are recruited 
to repair infrequent DNA alterations that can have fatal consequences if not 
repaired.  
Thus, DNA repair is vital to maintaining genome integrity, and therefore 
preventing cancer formation and age-related disease. 
1.2.6. DNA damage and its consequences 
Failure to repair DNA lesions may result in blockages of transcription and 
replication, mutagenesis, and/or cellular cytotoxicity79.  In humans, DNA damage 
has been shown to be involved in a variety of genetically inherited disorders, in 
aging (for review see Finkel80 and in carcinogenesis (for review see Hoeijmakers81. 
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Given the established association of defects in DNA repair with human disease, it is 
clear that mutagenic and  cytotoxic potential of DNA lesions is based on the degree 
of initial DNA damage and the ability of the cell to execute DNA repair73. This may 
have broad implications for viruses like HPV that normally maintain their genomes 
as extra-chromosomal episomes but for which integration of virus DNA is a prime 
proof for progression to cancer.  
 
1.3. Human papillomavirus 
1.3.1. HPV and their association with cervical cancer 
Cervical and other genital infections are commonly sexually transmitted. 
Human papillomavirus (HPV), the most prevalent sexually transmitted disease, 
affects more than half of all sexually active men and women at some point in their 
lives as shown in Figure 1.8 82,83. 
Infections by HPV are important etiological agents of cervical cancer, the 
second most common cancer in women worldwide84. Research demonstrates that 
infection with HPV leads to cervical cancer, accounting for over 90% of lesions 
associated with certain types of HPV82,85,86. Most HPV cases turn out to be benign, 
but nearly every cervical cancer is associated with infection by one of the “high risk” 
cancer-causing forms of the virus. The virus infects about 20 million people in the 
U.S87. Cervical cancer causes 5,000 deaths in the U.S. and 250,000 deaths worldwide 
annually. For review, see7,88,89. The cost of treatment of sexually transmitted disease 
(STD) including HPV in the United States is over $8.4 billion. 
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Age standardized world rate per 100,000. HPV affects more than half of all sexually 
active men and women at some point in their lives. 
 
 
 
 
 
 
 
Figure 1.8: Incidence of cervical cancer. 
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1.3.2. Properties of HPV 
Papillomaviruses (PV) are a large group of species-specific epitheliotropic 
viruses that cause epithelial proliferations in a wide variety of animal hosts. HPV are 
small (52–55nm in diameter) non-enveloped viruses that belong to the genus  
Papovaridae; and contain a supercoiled, circular, doubled-stranded DNA 
(approximately 8 kb) within an icosahedral proteinous capsid as shown in Figure 
1.9.  
 
 
www.whyfiles.org 
 
Figure 1.9: Atomic model of Human papillomavirus (HPV).  
Non-enveloped DNA virus within an icosahedral capsid.  
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When enlarged under an electron microscope, one HPV virion looks like a golf ball. 
Based on tissue tropism, more than 100 different genotypes of HPV causing a wide 
spectrum of pathologies have been identified90. They are species and tissue specific. 
They can also be classified into two groups according to the route of infection. 
Cutaneotropic HPV infect the skin whilst mucotropic HPV infect the epithelia of 
respiratory, digestive and genital tract. The epithelial surfaces include all areas 
covered by skin and/or mucosa such as the mouth, throat, tongue, tonsils, 
intestines, vagina, penis, cervix and anus. 
The Bethesda classification (the most recent classification) for epithelial 
lesions caused by sexually transmitted HPV in the cervix indicates two major 
subsets of HPV82: the ‘’low-risk’’ types (mainly HPV-6 and HPV-11) and the ‘’high-
risk’’ types (mainly HPV-16 and HPV-18) as shown in Table 1.5. Both high and low 
risk HPV types target genital epithelia. ‘’Low risk’’ HPV are associated with low-
grade intraepithelial lesions, found in genital papillomas, mostly warts that often 
regress spontaneously. This mild-moderate dysplasia or condyloma is not cancer, but 
a precursor, neoplastic change prior to malignancy. The ‘’high-risk’’ types are 
associated with high-grade dysplasia or carcinoma. Figure 1.10 shows progression 
in the cells. In the Bethesda classification for cervical neoplasias, the “low grade” is 
equivalent to the previous mild or moderate dysplasia / cervical intraepithelial 
neoplasia (CIN) I or II, the “high grade” also representing the past severe dysplasia 
or carcinoma in situ (CIS) / CIN III. The current invasive cancer by Bethesda 
classification was defined by invasion through the basement membrane. 
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Table 1.5: High-risk and low-risk papillomaviruses. 
About 30 different HPV types infect the genital tract. Both the high and low risk 
HPV types target genital epithelia. 
 
 
HPV Classification 
 
 
HPV type 
 
 
High-risk  
 
16, 18, 31, 35, 39, 45, 51, 52, 56, 58, 59, 68, 
73 and 82 
 
 
Low-risk 
 
6, 11, 40, 42, 43, 44, 54, 61, 70, 72, 81 
and CP6108 
 
 
 
All HPV types share a related series of viral proteins and a common genomic 
organization. The open reading frames (ORFs) are transcribed from one strand of 
the viral DNA91. The HPV genome is organized into early (E), (functional) and late 
(L) (structural) genes, according to the time of their expression in its life cycle and 
the sequence homology of the viral genomes. For review see Howley92. Figure 1.11 
shows a diagram of the HPV-16 genome, a prototype of the subtypes known to 
cause cervical cancer.  
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HPV infection causes cervical intraepithelial neoplasia (CIN), which can develop 
into carcinoma with increasing disorganization of the epithelium following 
integration. 
 
 
 
 
 
 
 
 
Basal layer 
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High-risk HPV 
 
 
 
 
 
Figure 1.10: Classification schemes for intraepithelial neoplasias. 
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HPV genomes are double-stranded circular DNA and are organized into early (E) 
and late (L) genes. Long control region (LCR) is indicated in addition to start sites of 
transcription and polyadenylation signals for early and late messages. Organization 
of HPV-16 is similar to other HPV 
 
 
Table 1.6 depicts the HPV gene products involved with the biochemical 
processes and products necessary for virus replication and assembly91,93.  
 
Figure 1:11: Genomic map of HPV-16. 
 
 48 
 
 
Table 1.6: Known functions of HPV gene products. 
All HPV types share a related series of viral proteins and a common genomic 
organization. The open reading frames (ORFs) are transcribed from one strand of 
the viral DNA. The HPV genome is organized into early (E), (functional) and late (L) 
(structural) genes, according to the time of their expression in its life cycle and the 
sequence homology of the viral genomes. These proteins are necessary for virus 
replication and assembly. 
 
Region Protein 
 
Function 
 
E1 
 
Initiation of viral DNA 
replication (helicase) 
 
E2 
Transcriptional regulatory 
protein, auxiliary to E1  
 
E1∧E4 
 
 
 
Collapses the keratin network. 
Arrests cell in G2 phase of the 
cell cycle 
 
E5 
Transforming protein, interacts 
with growth factor receptors 
like PDGF 
 
E6 
Inactivates p53 by inducing 
degradation 
 
Early (E)* 
E7 
Inactivates pRb by inducing 
degradation and alteration of 
phosphorylation state 
 
L1 Major capsid protein 
 Late (L) 
L2 Minor capsid protein 
 
Regulatory 
Long control 
region (LCR) 
or Non-coding 
region (NCR) 
Origin of DNA replication, 
Control elements 
      
        *E3 / E8 proteins = Not made by all virus types 
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The early proteins are required for viral replication and transcription control 
whilst the late proteins for synthesis of new virus. The long control region (LCR) or 
non-coding region (NCR) has promoters and enhancers where DNA replication is 
initiated.  Thus, HPV utilize the host cell DNA replication machinery, together with 
at least two virally encoded nonstructural proteins (E1 and E2), to replicate their 
DNA episomally in squamous epithelium94. 
1.3.3. HPV life cycle 
HPV growth is species and tissue specific. Based on tissue tropism, over 100 HPV 
types have been sequenced with a subset of more than 30 types infecting genital 
squamous epithelium as shown in Figure 1.1295 of women and men (i.e.,vulva, 
vagina, cervix, foreskin). Infection with these sexually transmitted subtypes of HPV 
may lead to cervical cancer in women. Other squamous epithelial surfaces that may 
become infected by HPV include the hands, arms, feet, cells lining the mouth 
(tongue, tonsils), throat, intestine and the larynx93,95,96. The main targets are 
squamous epithelia. The epidermis is formed by multiple layers of keratinocytes and 
its differentiation process begins in the proliferative basal layer. Keratinocytes are 
the main cell type of the epidermis, and they are responsible for the formation of the 
cutaneous barrier at the fully differentiated surface. Keratinocytes are the primary 
target cells for HPV infection97. Compromise of the basement membrane appears 
essential for the virus to gain access to the basal epithelial cells at a site of wounding 
since they are the only cells that proliferate86.  
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Hematoxylin and eosin (H&E) stained normal squamous epithelium. A 
subset of HPV infects squamous epithelium of genital origin. The squamous 
epithelia are the main targets for HPV infection. 
 
 
 
The infectious unit is the epithelial “squame”. Following entry into the basal 
epithelial cells, HPV genomes are established by DNA replication to low copy 
number (50-100 copies per cell) and the daughter cells leave the basal layer and 
begin to differentiate. Because HPV are among the unique viruses because of having 
Figure 1.12: Human squamous epithelium. 
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a differentiation-dependent viral life cycle, replication is tightly linked to the cell 
differentiation program of the infected host cells98-100. Figure 1.13 shows the 
differentiating cell layers of epithelia with characteristics and events in the HPV life 
cycle in each layer of epithelia. As infected cells differentiate, the viral DNA is 
amplified to high copy number and infectious virus is produced and released as 
newly assembled capsids trappeed inside of “squames”99. Many viruses exhibit 
latent phase in addition to the productive portion of the viral life cycle101. In latently 
infected cells, HPV DNA may be present in the squamous epithelium but no 
differentiation-dependent synthesis of virions occur101.  Increasing disorganization 
of the epithelium occurs during progression to carcinoma. Progression to cancer 
requires integration of HPV DNA into the host genome. 
HPV are fastidious human pathogens. The inability of passage of HPV in vitro 
had previously been a major obstacle to working with HPV102. The studies of HPV 
had also been hampered by the lack of permissive cell culture systems for virus 
propagation. The HPV growth life cycle is completed only in differentiated host 
keratinocytes. HPV in vitro models containing integrated viral sequences like HeLa 
and SiHa cells have been used for viral pathogenesis studies. However, several cell 
lines obtained from HPV-infected clinical specimens contain episomal HPV 
including W12, and CIN 612 and very useful for the analysis of the productive 
stages of viral life cycle103. 
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Figure 1.14: Differentiating HPV-infected epithelium. 
The diagram shows a typical HPV-infected epithelium actively producing viruses 
with different differentiation layers. 
 
 
 
 
 
 
 
Basement membrane 
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Two model systems have developed and used successfully for production and 
investigation of various types of HPV and are the human epithelial tissue xenografts 
and the organotypic raft cultures99,102,104-106. The human tissue xenograft system in 
immunocompromised 107,108 developed by Kreider and Howett was the first to 
successfully grow HPV-11 virions outside the natural host109.  An additional system 
for virus production in which epithelial cells are grown at the air-liquid interface is 
referred to as organotypic ‘raft’ cultures (OTC)110, which has also permitted the 
study of high-risk types differentiation-specific aspects of HPV, including 
amplification of viral DNA, expression of late genes, and viral morphogenesis111. 
The xenograft system does not allow the study of the HPV life cycle by genetic 
manipulation of HPV genomes, but this is possible with HPV-11 in the raft 
culture112.  
1.3.4. Mechanisms of HPV pathogenesis 
High-risk HPV are the major etiologic agent of carcinoma of the cervix.  About 50% 
of cervical cancers are due to HPV-16113,82. HPV requires co-factors that may 
enhance its lesion progression and integration. Thus, while viral infection serves as 
the initiating event; it is a necessary prerequisite for the development of most 
cervical cancers. However, it is not by itself sufficient indicating that secondary 
mutational events are also required86. The hypothesis that HPV by itself increases 
mutation rates cannot be excluded. Moreover, not all women infected with high risk 
HPV develop cervical cancer. Depending on the degree of disruption of epithelial 
differentiation84, cervical intraepithelial neoplasia (CIN) I , a precursor to cervical 
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cancer114 and CIN II (mild-moderate dysplasia), may progress  to CIN III, invasive 
cervical cancer82,91,115 as shown in Figure 1.10. Vaginal formulations of spermicides 
such as N-9 or other pharmaceuticals can also be introduced into the epithelial 
environment and may promote HPV lesion progression and integration as a result 
of the irritation, epithelium disruption and other damages caused30. Agents 
introduced into the vagina (either topically or from the blood stream) can possibly 
act as a co-factor for HPV-associated cervical cancer. Integration of the high risk 
HPV causes the cell to progress to the cancer state. Besides HPV infection and 
integration, additional risk factors for cervical cancer include immune status, parity, 
oral contraceptives and viral cofactors, tobacco smoking, HIV/AIDS and other STD 
co-infection notably Chlamydia trachomatis and other unknown factors116,115,117,118. 
Smoking for example increases cervical cancer risk by 4.5-7.0 fold, though the 
mechanism is not clear. For review, see Harris115 and Ylitalo119.   Figure 1.14 shows 
the pathology of HPV-induced cervical cancer101,115. Episomal maintenance of the 
HPV genome is essential for the productive HPV life cycle120 . Integration of HPV 
DNA into the cellular chromosome usually precedes the progression of a low-grade 
to a high-grade lesion121 
High-risk HPV such as HPV-16 is frequently found integrated into cervical 
cancer cell genomes and these integrations are thought to play a role in 
tumorigenesis. The first genes to be expressed following infection are the viral 
replication proteins, E1 and E2122. Integration of the viral genomes into the host 
DNA plays an important role in the progression to malignancy, which disrupts E2,  
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Figure 1.15: HPV reproductive cycle and possible progression to cancer. 
High-risk HPV infection causes carcinoma. Genital warts may become malignant if 
they remain unchanged/fixed.   
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resulting in over-expression of the high-risk HPV E6 and E7 in malignancy86,121,123. 
Expression of E6 and E7 proteins enhances their selective growth advantage and 
therefore increases the frequency of foreign DNA integration into the host 
genome121. 
Because ‘high-risk’ E2 from episomes down-regulates these high-risk HPV 
oncogenes, the integration of viral genomes relieves these repressive activities of E2 
on E6/E7 transcription and allows for increased expression of these viral  
oncogenes86 which also stabilizes the E6/E7 mRNAs123. Normal cell division is 
regulated by the retinoblastoma (Rb) and p53 genes. E6 and E7124,125 exert their 
oncogenic properties by different means as shown in Figure 1.15. E6 induces 
degradation of the tumor suppressor gene, p53, and E7 binds to and inactivates the 
product of the Rb tumor suppressor gene,  
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Figure 1.16: Deregulation of the cell cycle by HPV-16 E6 / E7 oncogenes. 
Cellular tumor suppressors p53 and Rb play an important role in controlling cell proliferation. These 
cell cycle regulators are targeted for inactivation by HPV-16 via interactions of its E6 and E7 
oncoproteins with p53 and pRb, respectively. p53 plays a central role in a signal transduction 
pathway that mediates G1 arrest after DNA damage. E6 directly targets p53 for degradation whilst E7 
through the interaction with pRb, one of the potential downstream effectors of p53. E7 binds to pRb 
resulting in the release of active E2F, which induces the transcription of cellular genes involved in 
DNA synthesis and cell cycle progression in S-phase. Loss of p53 function through interaction with 
E6 protein of high-risk HPV types is an essential event regarding cervical carcinoma development. 
Thus expression of either of the HPV-16 encoded E6 and E7 oncoproteins allows cell cycle 
progression following DNA damage. Expression of E6 and E7 proteins enhances their selective 
growth advantage and therefore increases the frequency of foreign DNA integration into the host 
genome. Adapted from Fields Virology, 1996. 
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blocking their effect on regulating cell division126; this drives proliferation126. Other 
tumor suppressor gene functions are regulators of cellular responses to DNA 
damage, initiation of DNA repair and replication, induction of apoptosis and 
promotion of cell differentiation 127. Inactivation of the p53 tumor suppressor gene is 
correlated to a critical step in the development of many human cancers128.  
Mutations in p53 gene (with or without associated allelic deletions) are among other 
inactivation events and binding of the p53 to cellular or viral proteins therefore 
results in abolishment of the normal G1 check point of the cell cycle regulation that 
cells normally display in response to DNA damage129,130. Loss of p53 function 
through interaction with E6 protein of high-risk HPV types is an essential event 
regarding cervical carcinoma development131. Retinoblastoma is a key protein 
controlling entry into the S-phase of the cell cycle regulation132,133. The ratio of E2 to 
E6 using quantitative RT-PCR or absence of intact E2 following electrophoresis of 
Alu-PCR products therefore may be used to determine if integration has occurred. 
Observation of viral-cell transcripts and chromosomal deletions associated with 
HPV integration may indicate that such events are part of a multi-step mechanism 
leading to the development of cervical cancer.  
1.3.5. Role of HPV infections in the development of cancer 
Early diagnosis is effective in preventing progression to cervical cancer and 
relies on screening the population through the use of the Papanicolau (Pap) smear. 
The Pap smears, widely available in developed nations has led to early detection of 
precancerous lesions and a decline in mortality from cervical cancer134,135. Other 
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screening programs e.g., visual inspection with acetic acid and colposcopy and the 
HPV DNA testing [approved by the U.S. Food and Drug Administration (FDA)] are 
used in conjunction with Pap smear. HPV is part of, and occurring within, a much 
larger STD epidemic. There is no treatment for HPV infection. HPV’s presence on 
the horizon and its incidence are increasing globally. Benefits may outweigh 
concerns associated with usage of the two HPV vaccines, Gardasil® and Cervavix™. 
The hallmark of HPV infection is the development of benign genital warts with 
majority of conditions being sub-clinical and hence undetectable. The highest rates 
of HPV infection occur in the adults with males and females having similar 
prevalence rates. Cancer is most likely to develop in women ages 35 and older 136,83. 
The incidence of cervical carcinoma increases steadily with age starting at 20 years 
and reaching a peak at 40 to 50 years 137. Vertical transmission of HPV can occur 
during delivery through the birth canal resulting in recurring laryngeal papillomas 
in neonates and children138-140. This may result in obstructive lesions in the airways. 
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Specific Aims: 
  Each specific aim has been designed as a manuscript. 
  2. A new method for assessing microbicide safety: DNA damage and 
   recovery after exposure to nonoxynol-9 (N-9) and the alkyl sulfate 
   microbicide, sodium dodecyl sulfate (SDS) 
   To determine DNA damage in response to N-9, or SDS exposure in the 
   human cervical carcinoma cell line (HeLa cells) 
   3. DNA damage and repair in human epithelial cells carrying HPV-16 
      episomes promote virus DNA integration 
    To assess in vitro if N-9 treatment increases risk of high-risk HPV DNA  
    integration into the host DNA. 
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2. A NEW METHOD FOR ASSESSING MICROBICIDE SAFETY: DNA        
DAMAGE AND RECOVERY AFTER EXPOSURE TO NONOXYNOL-9 (N-9) 
AND THE ALKYL SULFATE MICROBICIDE, SODIUM DODECYL SULFATE 
(SDS) 
To determine DNA damage in response to N-9, or SDS exposure in the human 
cervical carcinoma cell line (HeLa) 
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2.1. Abstract 
High-risk human papillomavirus (HPV) such as HPV type 16 (HPV-16) and type 18 
(HPV-18) are found in the majority of cervical cancers. In cancers, the viral genome 
is integrated. Concomitantly, HPV-infected genital target tissues can be damaged by 
co-factors such as carcinogens and chemicals. Microbicides are substances that may 
prevent the transmission of human immunodeficiency virus type 1 (HIV-1) and 
other sexually transmitted disease pathogens when applied vaginally and, possibly, 
rectally. Topical microbicides could include cream, suppository, gel and film. 
Vaginal formulations like spermicides [e.g. nonoxynol-9, (N-9)] can also be 
introduced into the epithelial environment. N-9 is a non-ionic surfactant commonly 
found in vaginal gels, foams and condoms. Usage of N-9 in vitro against viral and 
bacterial pathogens prevented infection. Research in mice determined that N-9 has a 
high toxicity profile (i.e., increased lymphocyte infiltration and cytokine secretion in 
cervical epithelium). We hypothesize that the associated inflammation is likely to 
increase oxidation intracellularly (i.e., generate reactive oxygen species or ROS). We 
also hypothesize that some chemical agents and microbicides may directly induce 
ROS. ROS in many systems may cause oxidative DNA damage, usually single- or 
double-stranded breaks that may increase the risk of HPV DNA integration, and 
therefore increase the risk of progression to cervical cancer in high-risk HPV-
infected women. Based on toxicity studies (viability of cells, trypan blue exclusion 
method), HeLa cell lines were exposed to concentrations of N-9 that permitted 75% 
survival at ten minutes (based on cell counts) and another candidate spermicide / 
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microbicide, sodium dodecyl sulfate (SDS) at concentrations of 0.01% and 0.162 mM 
(equivalent of 0.01%). We applied the alkaline version of the single-cell gel 
electrophoresis (comet) assay to the treated HeLa cells to assess the genotoxicity 
response of DNA strand breaks of the compounds under study. Data were also 
collected using primary human keratinocytes. Findings enhance existing ideas on 
cellular toxicity following N-9 and SDS exposures. Both treatments induced 
compound-dependent and dose-dependent increase in DNA migration, expressed 
as mean tail moment in the comet assay. Our data indicate for the first that that N-9 
treatment at 0.01% causes significant DNA damage. SDS, when used at the same 
percent or same molar concentration is relatively less toxic although still inducing 
some DNA damage relative to control cells.  
Evaluating candidate microbicide formulations under the same testing conditions 
can help to distinguish between potential candidates likely to show promise as safer 
microbicides for the treatment and management of sexually transmitted infections 
(STI).  
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2.2. Introduction         
The assessment of DNA damage and repair through the technique of comet 
assay has made a tremendous contribution to the fields of genetic toxicology and 
biomonitoring based on the results of chemical exposures in human cells and 
humans141,142,143,144,145. 
Because topical microbicides and spermicide such as sodium dodecyl sulfate 
(SDS); a protype of alkyl sulfates and other spermicides notably nonoxynol-9, (N-9) 
designed to combat the spread of sexually transmitted infections (STIs) may be 
applied frequently, safety as well as efficacy are regarded as most important in the 
acceptability of these products. Primary concerns among women, the vulnerable 
population and men their spouses, are about long-term repeated usage side effects. 
A truly effective vaginal microbicide would provide broad-spectrum activity to 
reduce the susceptibility of women to sexually transmitted diseases, including 
infection with human immunodeficiency virus type 1 (HIV-1). The World Health 
Organization (WHO) has had to halt three large-scale clinical trials of potential HIV-
1 microbicides in recent years over safety concerns146,147,148. For review see the 2007 
IAS conference Abstract Numbers: WESS302 and TUPEC008. www.iasociety.org 
Certain spermicides / microbicides may subject women to an increased risk of 
acquiring infections. The trials failures were disappointing and an unexpected 
setback in the search for safe and effective microbicides. However these setbacks 
have only enhanced the resolve of the research community and agencies to find new 
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solutions. Thus, the early termination of these trials has emphasized the need for 
research into other compounds. 
With the documented in vitro and in vivo high toxicity profile of N-
9149,150,151,41,44,43,30, many other lead microbicides are being compared to N-930,152. N-
9, a spermicide in use for its contraceptive role does not function as an effective 
microbicide60,36,146,153. Erosion of the cervix and lymphocyte recruitment occurs 
consequent to N-9 exposure. Increased oxidative events in tissues are likely to occur 
due to lymphocyte infiltration43,30,154,42,146,39. We hypothesized that this 
inflammation is likely to promote DNA damage which may in turn increase the 
probability of high risk human papillomavirus (HPV) genome integration into the 
host genome in HPV infected women given that N-9 through reactive oxygen 
species (ROS) could cause DNA damage. Therefore, we decided to compare the 
alkyl sulfate microbicide, SDS to N-9 because other data had shown SDS to be less 
toxic relative to N-9 despite the fact that SDS is also a surfactant60,51. 
Detergents are essential solubilizing agents in the solubilization and 
purification of membrane proteins. Non-ionic detergents such as N-9 greatly interact 
with the lipid component of Ca2+-ATPase membranes below the critical micelle 
concentration (CMC), while ionic detergents such as SDS extracts Ca2+-ATPase 
before solubilization of lipid54. The CMC decreases with alkyl chain length and 
increases with introduction of double bonds, branched points and additives. The 
CMC values of N-9 and SDS are 0.085 ± 0.009 mM and 6-8 mM respectively. For 
review, see155,156,157. 
 66 
A number of compounds and topical microbicides have been tested for their 
potential to decrease the rate of STIs. For review see152,56,30. Environmental chemicals 
for example metals and pesticides have adverse effects on human 
population70,80,81,158. Acute and chronic exposure to N-9 and other environmental 
chemicals has been shown to produce marked toxicity at the target sites leading to 
inflammatory response51,80,30. Some of these chemicals may directly affect the DNA. 
Well-established methods for assessing the genetic damage and toxicity profile 
comprise chromosomal aberration, micronucleus assay and sister chromatid 
exchanges145. Evaluation of the genotoxic potential of these compounds employing 
non-proliferating cell populations, more sensitive test systems and less time-
consuming methods based on their ability to cause DNA damage have not been 
done. 
Cellular DNA is under constant challenge by exogenous and endogenous 
genotoxic stress, nucleotide mis-incorporation during DNA replication, and the 
intrinsic biochemical instability of the DNA itself result in both transient and 
accumulated DNA damage and genomic instability144,78.  All cells are equipped with 
DNA damage response pathways that trigger cell cycle arrest, DNA repair, and 
where necessary, apoptosis, to eliminate damaged cells. The maintenance of genome 
integrity and fidelity therefore, is essential for the proper function and survival of all 
organisms159.   
 The comet assay, also known as Single Cell Gel Electrophoresis (SCGE) assay 
is a microgel electrophoresis technique for detecting and quantitating a wide variety 
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of DNA altering lesions and DNA repair in vivo and in vitro at the individual 
eukaryotic cell level74,160,161,78,162 and also in some prokaryotic cells163,164,165,166. In this 
assay, broken DNA migrates from the nucleus to the anode providing images 
similar to comets. The length and fragment content of the tail (DNA liberated from 
the comet head) is directly proportional to the amount of DNA damage. This 
established method for studying factors altering mutagenicity and carcinogenity is 
rapid, visual and extremely sensitive detecting one break in 1010 daltons142. Other 
major applications of the comet assay include genetic toxicology testing, bio-
monitoring and nutritional research and human epidemiology. The comet assay 
measures double strand breaks (DSBs), single strand breaks (SSBs) and additional 
DNA structures such as alkali labile sites167,143,168,169,170. There is therefore the urgent 
need to develop new and sensitive screening methodology to measure the safety of 
spermicides/microbicides. 
The objective of this study in using the comet assay was to compare the 
characteristics of data for the healthy cell (untreated cells) to the treated cells (cells 
induced by the damage under investigation) in revealing the DNA-damaging effects 
and repair of N-9 toxic stimulus in the SCGE as a novelty.  
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2.3. Materials and Methods  
2.3.1. Microbicide and other tested compounds  
         N-9 was purchased from Spectrum Chemical Manufacturing Corp. (New 
Brunswick, NJ). SDS of high purity was purchased from BIO-RAD (Hercules, CA). 
Stock solutions of 2% N-9 and SDS were prepared in phosphate-buffered saline 
(PBS), (Mediatech, Inc. Manassas, VA) and used for HeLa cell exposure at a final 
concentration of 0.01%. Equivalent molar concentrations were also tested. The 
prepared stock solutions were kept at 40C and used within one week. Serial 
dilutions of stock in PBS were prepared fresh prior to each experiment.  
2.3.2. Cell lines and culture conditions 
 Cell cultures of HeLa and SiHa cervical carcinoma cell lines obtained from the 
American Type Culture Collection (Manassas, VA) ATCC # CCL-2 and ATCC # 
HTB-35 respectively were maintained in Dulbecco’s modification of Eagle’s minimal 
essential medium  (DMEM), (Mediatech, Inc. Manassas, VA) supplemented with 
10% heat-inactivated fetal bovine serum (FBS), (Mediatech, Inc. Manassas, VA), L-
Glutamine and PennStrep media using conditions provided by the ATCC.  Cells 
were grown at 370C in 60- mm cell culture dishes. The HeLa cells contain integrated 
HPV-18 sequences with low p53 expression and normal levels of pRB 
(retinoblastoma suppressor)171,172. The SiHa cells contain one or two copies of 
integrated HPV -16 DNA173,174. Normal human epidermal keratinocytes (NHEK), 
neonatal and pooled cell line was purchased from Lonza (Walkersville, MD). 
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Keratinocytes were cultured in Clonetics® Keratinocyte Basal Medium-2 (KBM-2) 
supplemented with Clonetics® keratinocyte growth media-2 (KGM-2) bullet kit 
(Lonza) according to manufacturer’s instructions (Lonza Walkersville, Inc; 
Walkersville, MD). All cells were cultured as monolayers in exponential growth by 
subcultivation. Cells were grown at 370C in 60- mm cell culture dishes and growth 
media replaced every four days or based on the experimental requirements until 
cells reached 70% confluent. The Keratinocytes from Lonza were isolated from 
human tissue obtained under “informed consent.” As primary cells, NHEK were 
used for comparative studies with the HeLa cells. 
2.3.3. Treatment conditions     
  The HeLa cells used in this study were derived from cervical cancer cells. 
These human cervical cancer cell lines were seeded in 60-mm plates at a density of 
1.0x105 in 5 ml of growth media in triplicate according to each experimental 
grouping for a minimum of three days or until they reach 70% confluence. The 
culture medium was replaced with PBS as dilutions of tested compounds were 
made in PBS. This PBS-treated culture was handled as the negative control. Media 
only was added as additional control (data not shown in all treatments as they 
consistently proved the same as PBS treated). HeLa cells were exposed to 0.01% N-9 
and SDS and 0.162 mM N-9 and SDS. Hydrogen peroxide (H2O2), known DNA 
damage inducer was included as a positive control at a concentration of 50µM, 
initially at 100µM. Exposure of keratinocytes to test compounds was similarly 
handled in the same exposure conditions as the HeLa cells in-vitro. All treatment 
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groups in triplicate were incubated with the test compounds for 10 minutes at 370C.  
After harvesting, cells were counted and cell viability tested and immediately 
assayed for DNA damage.  
 
2.3.4. Alkaline Comet assay  
The Single-Cell-DNA Gel Electrophoresis (SCGE) or Comet assay (Trevigen, 
Inc.; Gaithersburg, MD) under high alkaline conditions (pH > 13.0) was used to 
measure DNA damage and its repair in individual cells; detecting not only frank 
DNA strand breaks (single and double), but, alkali-labile sites, DNA cross-linking 
and incomplete excision repair sites175,143. 
The procedure for measuring DNA damage in vitro has been described 
previously176,143,160,170,177,162 with slight modifications at the different steps. Briefly, 
individual sub-confluent cells grown in HeLa medium in 1:10 suspension with 
either untreated or with damaged DNA previously incubated at 370C for 10 min 
were embedded in agarose gels on microscope slides and lysed by the lysis solution 
(Trevigen® proprietary reagent) to remove cellular proteins, leaving the DNA as 
distinct nucleoids. Though proprietary, the lysis solution from the comet assay 
manufacturer’s kit has an alkaline pH and contains detergents and high salt 
concentration. All the steps described prior to cell lysis were conducted under a 
reduced light level to prevent additional DNA damage. DNA damage as strand 
breaks induces relaxation in the supercoiled DNA coils and generates small 
fragments of DNA. The liberated DNA is then subjected to a gel electrophoresis 
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procedure under alkaline conditions. As a result of the loss of DNA supercoiling, the 
electric current pulls the negatively charged DNA, represented by an increase of 
DNA fragments from the nucleus in the direction of the anode resulting in 
characteristic images like a ‘comet’ with a head (the nucleus) and a tail. During 
migration, the amount of DNA in the comet tail and the distance of migration can be 
used as a measure of damage. DNA comets from treated cells and untreated cells 
were examined after staining the slides with the fluorescence DNA-binding dye, 
SYBR Green 1 (1:10 dilution from concentrate; Trevigen, Gaithersburg) and the 
comet image captured by immunofluorescent microscopy using an Olympus IX-81 
Immunofluorescent microscope at a magnification of X400.  
The TriTek CometScore™ version 1.5 software (Sumerduck, VA) was used to 
score fluorescent comets based on DNA content (intensity) and score matrices. A 
random selection of at least 75 cells per sample was scored and used for analysis to 
give a representative result for the population of cells178. Among the variety of 
parameters provided by the computer-based image analysis for each comet, Tail 
moment was selected as the parameter that best reflected DNA damage (defined as 
the product of percentage of DNA in the tail and the tail length) for statistical 
analysis165,179,180. Each experimental group in triplicate treatments was repeated at 
least three times. In all experiments, untreated and hydrogen peroxide treatment 
samples were used as controls.  
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2.3.5. Viability assay  
  Cell viability was assessed using the trypan blue dye exclusion 
method181,182,183. In brief, trypan blue is a vital dye and reactivity is therefore based 
on the fact that the chromophore is negatively charged and does not interact with 
cell unless the membrane is damaged. Viable cells, thus exclude the dye, while dead 
cells stain blue due to uptake of it. However, this assay does not distinguish necrotic 
versus apoptotic cells, as it simply indicates if cell membranes are intact. A viability 
assay was performed to determine the test substance that gives at least 75% viability 
after 10 minutes of treatment at 370C.     
 Initial determination of this survival rate was performed to select 0.01% N-9 
as the standard concentration. Because topical spermicides and microbicides are 
often formulated as percent compounds, SDS was also tested at a 0.01%, even 
though that establishes slight differences in molarity. In subsequent comet assays, 
equimolar treatments of N-9 and SDS were also performed. 
2.3.6. Statistics 
Samples were tested in triplicate. All experiments were repeated two to four 
times to ensure reproducibility of results. All results were indicated in the form of 
mean ± standard error of mean (SEM). Data were analyzed and interpreted using 
the statistical and graphical functions of Microsoft Excel® and GraphPad Prism 3.0 
(GraphPad Software, San Diego, CA). Differences between the two groups of 
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treatment were statistically evaluated by Student’s t-test. Statistical significance was 
accepted at p<0.05. At least 75 selected cells were analyzed per sample. 
 
2.4. Results 
2.4.1. In vitro toxicity testing of N-9 on human cervical epithelial cells 
Human cervical epithelial cells, SiHa and HeLa (morphology of HeLa cervical 
cells shown in Figure 2.1) were cultured and at approximately 70% confluent, cells 
exposed to 0.01% N-9 at 370C for 10 mins and tested for viability by trypan blue dye 
exclusion test. The dye could not penetrate the intact plasma membrane of viable 
cells but crossed the broken plasma membrane of dead cells.  Each treatment group  
had its own control, which is a type of control for every variation in the time of the 
experiment.  As shown in Figure 2.2, after 10 min exposure to 0.01% N-9, about 75% 
viable cells were present in both cells. Sensitivity of the cells to N-9 was indicated by 
 increased cytotoxicity with time. This decreased cell viability during continuous 
exposure to N-9 was seen in both cell lines.  
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Source: By courtesy of American Type Culture Collection (ATCC), www.atcc.org 
 
 
 
HeLa cells are adherent, somewhat fibroblastic, epithelial cervical cancer cell line. 
They are representatives of cell types in genital tissues likely to be exposed to a 
topical vaginal microbicide. 
 
2.4.2. Effects of compound treatment on human epithelial-like cells  
The alkaline comet assay provides a sensitive tool for the detection of DNA damage 
(single-stranded breaks and alkali labile sites / lesions, capable of being transformed 
into SSB’s under alkaline conditions) at the single cell level. The appearance of the 
Figure 2.17: Morphology of HeLa cells. 
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comets differed depending on the compound treatment conditions. Figure 2.3 shows 
representative images from the HeLa cells. The negative control cells (A) 
demonstrate compact tight nucleoids. However, the cells treated with hydrogen 
peroxide (B) demonstrate a tail (hence the term comet) made up from DNA 
fragments. Thus, as the positive control, H2O2 induced DNA strand breaks and 
alkaline lysis. Moreover, (C) and (D) cells were treated with N-9 and SDS showing 
moderate and low amounts of DNA in the tails respectively. For image capture and 
analysis, these are typical samples for comet scoring. Generally, cells with a high 
level of DNA-damage show increased comet parameters. The tail length and tail 
DNA content are parameters used to measure the extent of DNA damage. The 
length and fragment content of the tail is directly proportional to the amount of 
DNA damage.  
It has been shown previously that detergent based microbicides such as SDS 
is less toxic than N-9 through the MTT assay60, resulted in detection of tissue 
disruption, irritation and inflammation in cervical tissues42,39,30. We extended these 
studies by determining if human cervical epithelial cells exposure to SDS or N-9 
could result in DNA damage. HeLa cells were treated for 10 min in vitro with these 
compounds and DNA fragmentation was assessed through the comet assay. PBS-
treated and hydrogen peroxide were equally added as negative and positive 
controls respectively. Due to influence on cell death and DNA repair as a result of 
potential effects of cell confluence and keratinization, DNA damage assessment was 
begun and performed before the epithelial cells reach 70% confluence.  
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Figure 2.18: Percent viability of human epithelial cells measured by trypan blue 
after exposure to 0.01% N-9. 
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Figure 2.2: Percent viability of human epithelial cells measured by trypan blue 
after exposure to 0.01% N-9, Cont’d.  
SiHa or HeLa cells were seeded at 1 x 105 in 60- mm plates. At ~ 70% confluence, 
cells were exposed to 0.01% N-9 at 37 0C for 10 mins. At various time points, cells 
were harvested, counted and cell survival assessed using 20% trypan blue diluted in 
PBS. In both cells, approximately 75% viable cells were present at 370C for 10 mins. 
Bars indicate SEM. Experiment was repeated two times in duplicate. Each treatment 
had its own control (untreated) due to background.  
 
 
 
 
 
 
B 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 (A) Untreated HeLa cells as negative control, (B) HeLa cells treated with 50 µM H202 
as positive control, (C) HeLa cells treated with 0.01% N-9,  (D) HeLa cells treated 
with 0.01% SDS. Incubation conditions of 370C for 10 min were the same for all 
treatments. These typical comets seen after alkaline SCGE are representative 
examples used for comet scoring. All images are 400X magnification. 
 
 
 
A  
C 
 
D 
B 
 
Figure 2.19: Sample images of comets (from HeLa cells) stained with 
SYBR Green I. 
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A minimum of 75 cells per sample was randomly selected for analysis. Tail moment, 
the product of percentage of DNA in the tail and the tail length was used for 
statistical analysis.  
Figure 2.4 shows a comparison between 0.01% N-9 (A) and 0.01% SDS (B) in 
HeLa treated cells. In the N-9 treatment significant DNA damage was detected 
following 0.01% N-9 exposure for 10 min (p<0.001, Student’s t-test) (Figure 2.4A), 
whereas in SDS under same treatment conditions;  less than N-9 was also detected 
reaching statistically significant difference  compared to the untreated (media-
treated and PBS-treated showed similar observations) controls as in N-9 (p<0.001, 
Student’s t-test) (Figure 2.4B). There was less increase in tail moment of SDS 
indicated by the fold increase of N-9: SDS in HeLa cells 10: 6 respectively. 
 Figure 2.5 shows what happens when in similar experiments, equimolar amounts 
equivalent to 0.01% N-9 were tested.  HeLa cells were treated in vitro with N-9 and 
SDS using the percent by weight (0.01%) and equimolar concentrations of 0.01% 
(0.162 mM). PBS-treated and hydrogen peroxide were equally added as negative 
and positive controls respectively. DNA damage was assessed as described in 
Section 2 (Materials and Method) of chapter 2. At least 75 cells were scored per 
sample. Data are from representative of three independent experiments showing 
mean + SEM from samples studied in triplicate. 
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                         A. 
 
0.01% N-9 for 10 min in HeLa cells
Untreated 0.01% N-9
0.0
0.5
1.0
1.5
***
***p<0.001, n = 3
Treatment groups
 
 
                           B. 
 
0.01% SDS for 10 min in HeLa cells
Untreated 0.01% SDS
0.0
0.5
1.0
1.5
***
***p<0.001, n = 3
Treatment groups
 
 
Figure 2.20: N-9 induces relatively more DNA damage than SDS in HeLa cells. 
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Figure 2.4: N-9 induces relatively more DNA damage than SDS in HeLa cells, 
Cont’d.  
Alkaline comet assay in treated HeLa cells with 0.01% N-9 (A) and 0.01% SDS (B). 
Plots were generated by graphical and statistical functions of Excel and GraphPad 
prism. The treated was compared to the untreated and differences between the two 
groups of treatment were statistically evaluated by Student’s unpaired samples 
(two-sample), one-tailed t-test. H202 data not shown. Bars indicate SEM of means 
from three independent experiments, each containing triplicate measures of which a 
representative is shown. Statistical significance was accepted at p<.05. 
 
 
 
In the percent by weight experiment, both N-9 and SDS demonstrated significant 
DNA damage following 10 min exposure (p<0.001 and, p<0.0019 Student’s t-test 
respectively) (Figure 2.5A). The percent fold increase of N-9:SDS was 11:5. Similarly, 
in the 0.162 mM treatments, both N-9 and SDS demonstrated significant DNA 
damage following the 10 min exposure (p<0.001 and, p<0.001 Student’s t-test 
respectively) (Figure 2.5 B). The equimolar fold-increase of N-9: SDS was 12:4. The 
overall fold increase of percent to equimolar concentrations was 2.0:3.0 respectively. 
 
2.4.3. Effects of compound treatment on human keratinocytes and other       
epithelial-like cells. 
In assessing the ability of N-9 to cause DNA damage levels following 
exposure to other cells with different levels of p53, a cellular tumor suppressor 
regulating cell cycle check-point control after DNA damage; we used the normal 
human epidermal keratinocytes (NHEK) to obtain measured tail moment in the 
comet assay.   
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                  A. 
 
 
 
 
                  B. 
 
0.01% N-9 equivalent molarity 10 min treatments in HeLa cells
Untreated 0.162 mM N-9 0.162 mM SDS
0
1
2
***
***
***p<0.001, n = 3
Treatment groups
 
Figure 21: N-9 induces more DNA damage than SDS following treatment with 
equimolar amounts (equivalent to 0.01% N-9) in HeLa cells. 
Percent by weight treatments
Untreated 0.01% N-9 0.01% SDS
0
1
2
***
**
           **p<0.01, ***p<0.001, n = 3
Treatment groups
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Figure 2.5: N-9 induces more DNA damage than SDS following treatment with 
equimolar amounts (equivalent to 0.01% N-9) in HeLa cells, Cont’d.  
Alkaline comet assay in treated HeLa cells with 0.01% N-9 / SDS (A), 0.162 mM N-9 
/ SDS (B). Plots were generated by graphical and statistical functions of Excel and 
GraphPad prism. The treated was compared to the untreated and differences 
between the two groups of treatment were statistically evaluated by Student’s 
unpaired t-test. H202 data not shown. Bars indicate SEM of means from three 
experiments, done in triplicate of which a representative is shown. Statistical 
significance was accepted at p<0.05. 
 
 
 
Human keratinocytes or HeLa cells were exposed in vitro to 0.01% N-9. The damaging effect 
of indicated concentration of N-9 in HeLa cells manifested significant DNA damage at 
0.01% ((p<0.001, Student’s t-test) (Figure 2.6A). However, N-9 effects in NHEK was less 
than in HeLa cells at 0.01% ((p<0.001, Student’s t-test) (Figure 2.6B). The fold increase of 
N-9 in HeLa cells (10:1) to NHEK (4:1) was therefore 10:4.  
 
2.4.4. In vitro DNA repair of N-9 on human epithelial cells 
Cellular DNA repair corrects damage to DNA before it can become a 
mutation leading to serious consequences such as cell death, cancer or age-related 
disease. DNA repair is thus the first line of defense against mutations that cause 
cancer. 
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0.01% N-9 for 10 min in HeLa cells
Untreated 0.01% N-9
0.0
0.1
0.2
0.3
0.4
0.5
0.6
0.7 ***
                   ***p<0.001, n = 3
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                          B. 
 
Untreated 0.01% N-9
0.0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
***
              ***p<0.001, n = 3
0.01% N-9 for 10 min in keratinocytes
Treatment groups
 
Figure 22: Comparison of transformed human epithelial and primary 
keratinocytes in DNA damage. 
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Figure 2.6: Comparison of transformed human epithelial and primary 
keratinocytes in DNA damage, Cont’d.  
Alkaline comet assay with 0.01% N-9 treated in HeLa cells (A) and human 
keratinocytes (NHEK) (B). 
Plots were generated by graphical and statistical functions of Excel and GraphPad 
prism. The treated was compared to the untreated and differences between the two 
groups of treatment were statistically evaluated by Student’s t-test. H202 data not 
shown. Bars indicate standard errors of means from three experiments, done in 
triplicate of which a representative is shown. Statistical significance was accepted at 
p<0.05. Strand breaks induced by N-9 respond to DNA repair in primary human 
keratinocytes better than HeLa cells perhaps due to different levels of 
p53.Organisms are equipped with the necessary DNA damage response pathways 
that trigger DNA repair, cell cycle arrest, and when required, apoptosis, to eliminate 
the DNA damage or damaged cells. Single-strand breaks occur the most per day yet 
it is the type of DNA damage easily and immediately repaired by the cell. 
Hypothetically, a sound approach to measuring repair capacity is to inflict DNA 
damage in cells and to monitor the speed at which they remove the lesions. 
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Monitoring the removal of DNA damage was used to measure cellular DNA 
repair. The comet assay makes the provision to follow the removal of DNA damage 
in cells incubated after low doses of compound treatment. HeLa cells were treated in 
vitro with 0.01% N-9 or 0.01% SDS and incubated at 370C for 10 min. Untreated cells 
(media only and PBS) and cells treated with 50 µM H202 were also incubated as 
negative and positive controls respectively. Cells were further incubated at 370C in 
medium to allow repair following compound removal. At intervals of time 0, 10, 30, 
60 and 120 min, samples were assayed for DNA damage. Based on DNA content 
and score matrices, at least 75 cells per sample were randomly selected for analysis.  
The DNA recoveries of N-9 and SDS from time zero through 120 min are shown in 
Figure 2.7 (A) and (B) respectively.  
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0.01% N-9 in HeLa cells
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Figure 23: Time course of in vitro repair of DNA damage in HeLa cells. 
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Figure 2.7: Time course of in vitro repair of DNA damage in HeLa cells, Cont’d. 
Alkaline comet assay for measuring DNA repair in treated HeLa cells with 0.01% N-
9 (A), 0.01% SDS (B). HeLa cells were treated with 0.01% N-9 or 0.01% SDS. After the 
initial 10 min incubation at 370C, cells were further incubated at 370C in medium to 
allow repair following compound removal. At intervals of time 0, 10, 30, 60 and 120 
min, samples were assayed by SCGE for DNA damage cellular repair. Bars indicate 
standard errors of means from three independent experiments, done in triplicate of 
which a representative is shown. Statistical significance was accepted at p<.05. 
 
 
This figure illustrates the comet assay assessment of damage repair (by mean Tail 
moment) as determined by measurement of residual comets following incubation 
for the five time points in HeLa cells (see Figure 2.7. caption) after 10 min 
treatments.  All treatments excluding media only (same as the PBS treated as 
indicated in treatment conditions) were compared to the PBS treated. At time zero, 
damage was identical with the untreated and the media only. The plots reveal clear 
time – response for the HeLa cells, with the most recovered time (120 min) 
displaying the greatest recoveries. For the most recoveries (60 min and 120 min), the 
majority of repair occurs before 60 min, while for the lowest recoveries (10 min and 
30 min), a significant measure of residual comet remains after 10 min. At 10 min the 
significant damage repair at 0.01% (p<0.001, Student’s t-test) was the same for the 60 
min significance.  
2.5. Discussion  
More than 50% of adults living with HIV-1/AIDS in sub-Saharan Africa are 
women184,185. Prevention technologies are a vital weapon in the battle against HIV-1 
and other pathogens causing the epidemic. Although traditional technologies such 
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as condoms are effective against these sexually transmitted infections, for many 
women they are not a viable option. For some women, social pressures and the need 
to negotiate with their partners can make condom use a difficult proposition. A 
microbicide, however, offers the potential for a woman-controlled defense against 
infection and disease. Microbicides may also offer significant health benefits by 
preventing transmission of STD other than HIV-1, and potentially offering another 
form of contraceptive185,186,8,187,188,189,2. Thus, microbicides are a real possibility and 
have the capacity to save millions of lives.  
We have introduced the novel concept of using the alkaline comet assay to 
measure the safety and any increased susceptibility through DNA damage and 
repair assessment levels as an important area to explore in the design and 
development of these female-initiated HIV-1 and other STD prevention methods190. 
The comet assay has been found as the method of choice for detection of DNA 
strand break damage in cells.  
In assessment of cell survival following exposure to 0.01% N-9 by exclusion of 
viable dye (trypan blue), the percentage of viable cells results from 10 minutes 
treatment in both cells was used to select at which exposure to N-9 will reduce 
viability by 25%51. This “dose-finding test” adheres to the test kit manufacture’s 
recommendation that viability assay to be done with at least 75% viable cells before 
performing comet assay (Trevigen, Inc.; Gaithersburg, MD).  
The molecular weights of the tested compounds were different. N-9 (617g) is 
almost twice that of SDS (289g). Therefore, to effectively compare the DNA 
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damaging levels of N-9 and SDS, we normalize number of moles 0.01% being used 
for exposure by incorporating equivalent molarity concentrations alongside the 
percent by weight concentrations as seen in Table 2.7.  
Comparison of the safety of SDS with that of the commonly used spermicide, 
N-9 since the 1950s, requires consideration of the different dependence on 
concentration of agent on cell membrane permeabilization rate. N-9 is a non-ionic 
detergent and disrupts the membranes of epithelial cells, bacteria, and viruses. SDS 
is an ionic detergent, which besides cellular membranes; denatures proteins on 
membranes.  
 
Table 2.7: Equimolar concentration of N-9 and SDS. 
Both percent by weight and molar concentrations were used. The 0.01% N-9 
equivalent molar concentration was 0.162 mM. In separate experiments, SDS and N-
9 were also compared at the same molarity (0.162%). 
 
 
Treatment concentration 
 
 
 
Compounds 
  
Percent 
 
 
Molarity of 0.01% 
 
 
Nonoxynol-9 (N-9) 
MW = 617  
 
0.01% 
 
0.162 mM 
 
 
 
Sodium dodecyl 
sulfate (SDS)  
MW = 289  
 
 
0.01% 
 
0.35 mM 
 
 
 
                           Established Critical micelle concentration (CMC) of 
                             N-9 = 0.085 mM and SDS = 7.0-10.0 (~ 8.0) mM  
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The interactions of the membranes with detergent at concentrations below close to, 
or above the critical micelle concentration (CMC) are critical. The CMC of SDS is 
dependent on salt concentration. It is 8.0 mM in water, 3.5 mM for 10 mM NaCl, and 
1.4 mM for 100 mM NaCl in water191,155. Although SDS has a high CMC and a low 
CMC molecular weight, it tends to bind tightly to cationic molecules because of its 
anionic nature. The CMC of non-ionic detergents on the other hand are not very 
much affected by salt concentration156. From Table 2.7, the in-use molar 
concentrations of N-9 and SDS were 0.162 mM and 0.35 mM, respectively 
corresponding with their CMCs indicated underneath the table.  For ionic detergents 
such as SDS, increasing the concentration of counter ions reduces the CMC, thus the 
CMC drops as the ionic strength is increased191. 
Because of the amphipathic nature of N-9 and SDS, hydrophobic compounds 
will be solubilized in water191. The SDS molar concentration (0.35 mM) used in the 
study therefore must be below the established CMC of SDS (8.0 mM). However, 
since N-9 (non-ionic detergent),  is not much affected by salt concentration, its molar 
concentration of 0.162 mM employed in the study has to be above the known N-9 
CMC of 0.085 mM156. 
Though N-9 is virucidal in vitro its activity is non-specific; indicating that 
virucidal levels may produce adverse effects such as epithelial disruption and 
inflammation of the genital mucosa33,192,193,194,195.   
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Non-treated cells were processed to control for endogenous levels of damage 
within cells, and for damage that may occur during sample preparation. This 
background levels of breaks control is the recommended test of cells acceptable 
condition for the comet assay analysis as the exclusion of viable dye (trypan blue) 
does not measure viability. For review, see Collins167. Since the hydrogen peroxide 
treatment served as positive control for each step of the comet assay and the 
dimensions and characteristics of the comet tail, resulted from the exposure of the 
HeLa cells to the hydrogen peroxide was different to those induced by the damage 
under investigation we compared the mean of the treated compound under 
investigation to the untreated control. This PBS treated was used to determine the 
characteristics of data for a healthy cell. Moreover, as range and sensitivity also 
depends on assay calibration standard cells such as pooled lymphocytes with 
similar measure of damage each time assay is performed could be included in the 
analysis. For review, see Collins167,190. 
In assessing cytotoxicity through the trypan blue method, we avoided 
prolonged exposure of the cells to trypan blue since uptake of the stain is time 
sensitive. If exposure is more than 30 minutes, some viable cells may absorbed the 
stain, resulting in an increase in the number of trypan blue-positive cells and 
therefore equivocal results. Obviously, published reports indicate that 0.01% N-9 
and SDS will kill cells at longer exposures60; but this short exposure allowed 75% 
survival and measurable DNA damage. The treatment concentration therefore of 
0.01% (0.162 mM) of the tested compounds was non-lethal to the cells. 
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Usage of other epithelial cells, notably the primary keratinocytes was to 
identify the effect of microbicides on primary keratinocytes viability. This finding is 
appropriate to microbicide tolerance as the epithelial cells are part of the physical 
barrier that may inhibit entry of STD pathogens. Potential compounds 
compromising this barrier may increase the risk of the STD pathogens acquisition 
and transmission.  
In the analysis of data, microbicides could cause DNA damage. These believe 
is based on the fact that as these compounds interact with cell membranes, they 
cause irritation and inflammatory processes that might increase cell permeability. 
Regarding the interaction between reactive oxygen species (ROS) and DNA with its 
subsequent damage to the DNA, ROS are formed as by-products of mitochondrial 
aerobic respiration, as induced products upon exposure to certain 
environmental/exogenous agents (e.g. ionizing radiation), or as intended products 
during the immune response against invading foreign microbes. N-9 caused more 
DNA damage than SDS, though both are surfactants. N-9 treatment thus was 
associated with DNA damage that may increase HPV DNA integration into host 
genome and therefore increase the risk of cervical cancer. Based on fold increase of 
DNA damage, relatively N-9 and SDS manifested moderate recovery relative to the 
untreated cells before and after compound recovery as shown in Table 2.8. The ratio 
of DNA damage of the N-9 was approximately 9:1 relative to the untreated (negative 
control) before microbicide mediation and approximately 4:1 after microbicide-
mediated. Likewise, the ratio of DNA damage of the SDS was approximately 5:1 
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relative to the untreated (negative control) before microbicide mediation and 
approximately 3:1 after microbicide-mediated. Testing of N-9 and other candidate 
microbicides ability to cause DNA damage is novel.  
DNA repair is an important determinant of cell pathology, as un-repaired 
DNA damage plays an important role in the initiation and progression of cancer. 
Cells treated with H2O2 shows strand breaks as the major lesion in DNA, though 
oxidation of bases may occur. Rejoining of these induced breaks is usually rapid.  
 
Table 2.8: DNA damage fold increase of N-9 and SDS. 
HeLa cells were exposed to 500 µL of 0.01% N-9 and 0.01% SDS. To assess 
immediate and repaired DNA damage, cells were applied in the Single Cell Gel 
Electrophoresis (SCGE) assay either 10 min post-application or after 10 min for 
recovery following compound replacement with growth medium. Three 
independent experiments were performed, each in triplicate, with at least 75 cells 
scored in each treatment group. Fold increase is the ratio of mean tail moment of 
treated to untreated control. Data before and after recovery from partial DNA 
damage are presented for comparison. 
 
 
Treatment 
 
Immediate DNA damage 
(10 min treatment) 
 
DNA damage after recovery period 
(10 min treatment / 10 min 
recovery) 
 
 
N-9 (0.01%) 
 
 
9:1 
(n = 5) 
 
4:1 
(n = 3) 
 
 
SDS (0.01%) 
 
 
5:1 
(n = 3) 
 
 
3:1 
(n = 3) 
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In the N-9 and SDS time response repair, time zero indicates that DNA damage does 
not occur immediately after exposure of cells to N-9 or SDS. The rate of repair seems 
about the same. Also the final level of DNA damage seems about the same, even 
though N-9 started out with more damage. Moreover, granting an increasing trend 
of repair with time, 100% recovery could not be achieved, probably there was an 
irreversible damage / cells could not recover or extended recovery time is necessary. 
Accumulative DNA damage could result from inactivation of DNA repair 
mechanisms, DNA damage in excess of the cells repair capacity or DNA damage 
that is incapable of being repaired. Using the trypan blue dye exclusion assay for cell 
count, there was decreased number of cells with longer compound exposure (data 
not shown). For the immediate damage and 10 min recovery, both with initial 10 
min of treatment, based on the fold increase; there was some recovery from partial 
DNA damage with N-9 responding less to DNA repair perhaps as a result of the 
initial greater amount of DNA damage caused than SDS as shown in Table 2.8. Also 
since the two negative controls, media only and PBS only had almost similar levels 
of background damage, which further confirms our usage of PBS only as the 
untreated negative control. If appropriate, lesion-specific endonucleases could be 
included in the assay for measuring DNA repair. 
Despite the advantages of the comet assay as a test system for microbicide 
safety studies, it is without shortcomings. Among these are lack of uniformity in the 
test procedures and the biological importance of the DNA alterations detected. The 
damage caused by the ROS may not be enough to cause apoptosis and since the 
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cellular mechanisms correct damage to DNA before fixation as mutations. These 
detectable strand breaks are rejoined within shorter time points. Moreover, rejoining 
of DNA strand breaks by most cell types is known to be a rapid process, with a half 
time of a few minutes. For review see Faust144, Kassie145 and Frankenberg-
Schwager196. 
The SCGE detects repairable DNA alterations or alkali-labile sites capable of 
converting to single-strand breaks, while cytogenic tests detect fixed mutations 
persisting one mitotic cycle as a minimum145. Figure 2.7 shows the recovery of DNA 
damage at various time points in HeLa cells following exposure to N-9 and SDS. 
Time extension for N-9 and SDS recovery may not be indicated, as based on trypan 
blue assessment of cells, they were being killed by the surfactant with prolong 
exposure. N-9 and SDS caused DNA damage after 10 min of treatment at 0.01%., N-9 
> SDS.  Moreover, DNA damage was partially repaired after 10 min at 0.01%, N-9 < 
SDS.  
In the analysis of general epithelial cell types sensitivity to N-9, strand breaks 
are repaired in many different ways in other cells. For example, single strand breaks 
respond to DNA repair in primary human keratinocytes better than HeLa cells 
perhaps due to different levels of p53. ATCC has reported that HeLa cells express 
low levels of p53 and normal levels of pRb (retinoblastoma suppressor). Oncogenic 
HPV E6 and E7 inactivate the products of p53 and Rb tumor suppressor genes, 
respectively. P53 and pRb functions include regulation of the cell cycle and the 
cellular response to DNA damage, initiation of DNA repair and replication, 
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induction of apoptosis and promotion of cell differentiation127. Inactivation of p53 
may result from events such as mutation of the p53 gene (with or without associated 
allelic deletions) and binding to cellular or viral proteins like HPV-16 E6 in cervical 
cancer131. Hence, loss or diminished p53 function is associated with many forms of 
human cancers128. For review, see197,171. 
In the field of topical spermicides and microbicides, concentrations are 
frequently expressed as percentage. SDS was also tested at a 0.01%, even though that 
establishes slight differences in molarity, as trypan blue cytotoxicity assay was not 
done. In subsequent comet assays, performance of the equimolar treatments of N-9 
and SDS as compared to the percent treatments, they were almost the same. Though, 
representatives showed slight difference with the fold increase from the percent to 
equimolar being 2:0 to 3.0, respectively.  
A comparison of the topical microbicides and spermicides demonstrated that 
for the alkaline version of the comet assay, based on fold determinations; on 
increasing order, SDS is less damaging relative to N-9. The monitoring of DNA 
repair in human cells in this way (assessed by Comet assay) is a novelty. 
In summary, the results of these studies demonstrating that the comet assay 
as a good predictive measure of strand breaks in the DNA of single cells, N-9 is 
more damaging than SDS which well correlates with previous findings proposing 
that N-9 has a high toxicity profile than SDS51,149.  Taken together, the assays utilized 
in this study represent suitable screens for the assessment of candidate microbicides 
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safety. SDS could have multiple uses such as replacing N-9 as the alternative 
spermicide in male latex condoms and further development as a 
microbicidal/spermicidal personal lubricant. This type of modeling of microbicides 
interactions with epithelial cells found in the cervix and vagina should help identify 
and evaluate possible harmful effects before clinical trial. Further studies are 
required to evaluate the alkaline comet assay method completely as a valid 
predictive test of spermicide/microbicide safety. 
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     episomes promote virus DNA integration 
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integration into the host DNA in HeLa cells. 
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3. DNA DAMAGE AND REPAIR IN HUMAN EPITHELIAL CELLS CARRYING 
HPV 16 EPISOMES PROMOTE VIRUS DNA INTEGRATION 
 
3.1. Abstract 
Human papillomavirus type 16 (HPV-16) is most often integrated into 
cervical cancer DNA of the host cells. This integration into the human genome is an 
important occurrence in cervical carcinogenesis. 
Several risk factors for the progression from the intraepithelial neoplasia, the 
precursor to carcinoma with disorganization of the epithelium may contribute to the 
viral oncogene over-expression, which down regulate tumor suppressors and may 
drive integration.   
 DNA damage is caused by many different sources due to generation of 
reactive oxygen species (ROS). To maintain the integrity and fidelity of the cellular 
genome and the proper function and survival of organisms, all cells are equipped 
with DNA damage response pathways that trigger cell cycle arrest, DNA repair and 
where necessary, apoptosis to eliminate damaged cells. DNA damage and repair 
and smoking are major co-factors leading to invasive carcinoma formation. 
As a consequence of our previous finding via the comet assay that 0.01% N-9 
treatment is associated with elevated DNA damage we decided to investigate 
whether this phenomenon may increase HPV DNA integration into host genome 
and therefore facilitates an increased risk of cervical cancer. 
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 Integration, a consequence of HPV infection is associated in 99% of cervical 
lesions.  To investigate the relationship between potential DNA damage by chemical 
agents known to cause such damage including topical spermicides and microbicides 
and their effect on cervical cancer progression, we exposed epithelial cells to 0.01% 
of nonoxynol-9 (N-9) and analyzed the HPV-16 integration from the non-
tumoregenic cell line W12 with high copy numbers that stably maintain HPV-16 
genomes episomally. PCR to detect intact episomal HPV-16 DNA and integrated 
HPV-16 PCR to detect integrated HPV-16 DNA were conducted. The evidence of 
viral gene interruption and chromosomal deletions linked with HPV integration 
were perhaps indicative that such events may facilitate the multi-step mechanism 
and therefore increase the risk of cervical cancer.     
 
 
3.2. Introduction 
In the majority of cervical carcinomas, high-risk human papillomavirus (HR-
HPV) DNA is found integrated into host DNA, whereas in pre-invasive cervical 
lesions, the viral DNA is mainly in the episomal form120,198. HPV DNAs exist in a 
circular (episomal) state and kept in the basement membrane at 50-100 copies per 
cell99,105. HR-HPV integration is linked with selective growth advantage of affected 
cells and therefore, integration is pivotal in cervical tumor progression. Although 
episomal integration is a critical event in HPV-related oncogenesis, information 
available concerning the effect of integration on the host transcriptome is 
inadequate199. 
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Human papillomavirus type 16 (HPV-16) is associated with fifty percent of 
cervical cancers113,200. Integration of DNA happens in cancer developmental early 
stages and is a key event in malignant transformed cervical cancer. In more than 
seventy-five percent of invasive cervical carcinomas, HPV-16 genome is integrated 
into the host genome201,202, whilst in condylomas (genital warts) and in pre-invasive 
cervical lesions, the viral genome is usually maintained exclusively as an 
episome201,203,204,205. However, not all cervical intraepithelial lesions (CIN), the 
known precursor for the greater part of cervical cancers; containing HPV develop 
into invasive cancers206 and hence indicate that additional events are required for 
such neoplastic progression and also as integration is not part of the normal life 
cycle of HPV. 
 Infection with HPV-16 is necessary but not sufficient to cause cervical cancer. 
HPV-16 requires co-factors to enhance its lesion progression and integration. 
Integration of HPV-16 DNA into host chromosomes therefore necessitates other risk 
factors including parity, oral contraceptives, other viral cofactors, tobacco smoking 
and other unknown factors116,115.  Smoking and usage of chemicals leading to DNA 
damage increase risk of cancer by 4.5-7.0 fold with high toxicity profile207,119. 
Inactivation of the cellular tumor suppressor genes, retinoblastoma (pRb) and p53 
also enhance development of most cervical cancers, especially as a result of their 
binding and subsequent inactivation. Consequently, HPV-16 integration is part of a 
multi-step mechanism leading to the development of cervical cancer. 
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Examination of integration sites and flanking genomic DNA in cancers 
indicated that integration of viral DNA into the host DNA may be accompanied by 
change of the episomal HPV DNA. For review, see Stoler208. Integration of HPV-16 
DNA into the genome of cervical epithelial cells is more often than not linked to the 
interruption of the E2, a viral gene essential for DNA synthesis; open reading frame 
(ORF) of HPV209,210,211, thus deregulating expression of the E6 and E7 viral 
oncogenes and providing selective growth advantage in mixed cell 
populations212,213. The over-expressed E6 and E7 oncoproteins presumably leads to 
further improvement of the genomic instability associated with degradation of p53 
and or pRb function. Integration of HPV-16 genome into cellular DNA is 
accompanied with persistence of E6 and E7 that exert their oncogenic properties in 
different means.  Thus, they are independently able to immortalize various human 
cell types in tissue culture, but when they are co-expressed, their efficiency is 
elevated214. The HPV-16 E6 and E7 proteins interact with p53 and pRb 
respectively132,215,130, causing their inactivation and degradation171,216 possibly 
promoting the development of cancer210.  In this way, HPV-16 E6/E7 interactions 
with p53/pRB promote cell progression and prevent tumor suppressors-mediated 
apoptosis and growth arrest. Expression of HPV-16 E6/E7 proteins therefore 
enhances their selective growth advantage and increases the frequency of foreign 
DNA integration into the host genome121.  
p53 senses cellular DNA damage induced by DNA strand breaking agents217 
and prevents division of compromised cells in G1 checkpoint. E6 binds and target 
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p53 for ubiquitin-mediated ATP-dependent degradation171 and thereby prevent 
trans-activation of p53 responsive genes and allow cell cycle progression following 
DNA damage. The G1 arrest checkpoint to this extent may trigger to protect genomic 
integrity and fidelity and moreover allowing fragmented cells to undertake DNA 
repair and avoid the fixation of mutations. Increased DNA double-strand breaks are 
linked with HPV-16 episomal loss and integration in cervical keratinocytes. For 
review, see Winder218. 
Interspersed repetitive sequences (IRS) could be found in high copy number 
in majority of higher organisms. Human DNA comprise of groups of IRS elements 
such as Alu repeats. Though Alu elements are not uniformly distributed219, an Alu 
repeat is supposed to be located at an average of every 3-6 kilo base pairs (20-22)220.  
Although, integration of the HPV-16 causes the cell to progress to the cancer 
state; sensitive and reliable techniques for detection of integrated DNA induced by 
DNA strand breaks in vitro are limited.  
Methods used to distinguish between episomal and integrated HPV DNA 
among others are in situ hybridization221,222, restriction enzyme mapping followed 
by southern blot hybridization223,224, two-dimensional gel electrophoresis201 and 
anchored PCR225. However, in situ hybridization and southern hybridization lack the 
needed sensitivity to detect very low copy numbers against a strong background of 
episomal HPV DNA, though provides direct evidence of viral integration. 
Specifically, the anchored PCR amplification based approach demands high 
technical know-how in the enzymatic alterations of nucleic acids in PCR handling225, 
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despite the fact that it directly addresses integration with good sensitivity allowing 
complete analyses of integrated segments of HPV DNA226,227. Moreover, these 
methodologies rely on biased explanation, require very large sample size and 
therefore their inability to differentiate between integrated and episomal HPV DNA.  
To investigate the HPV integration occurring within sequences of an Alu 
repeat, we proposed the analysis of HPV-16 integration from the unique polyclonal 
cervical keratinocyte cell line W12, which stably maintains HPV-16 episomes105,228,229 
using integrated HPV-16 Alu-polymerase chain reaction (PCR), a sensitive non-
radioisotopic method. This specific PCR was used to amplify integrated HPV-16 
sequences by virtue of their likely linkage to known interspersed repetitive 
sequences. UV spectrophotometry was applied to the extracted DNA to determine 
the purity and concentration of the extracted DNA. In confirming that the desired 
band is amplified and also determining if there are other bands that may result non-
specific annealing and amplification, gel electrophoresis was done. Viral sequences 
in host genome were conducted by HPV-16 integrated Alu-PCR to isolate human 
polymorphic markers during viral integration, which assessed HPV DNA 
integration following DNA single- and double-strand breaks (SSBs and DSBs) in 
W12 cells. Strand breaks were induced by compound treatment of Nonoxynol-9  (N-
9) through generation of reactive oxygen species (ROS).    
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3.3. Materials and Methods           
3.3.1. Cells and culture conditions  
Cell culture of W12 cells, human cervical keratinocyte cell line was a gift from 
Dr. Craig Meyers of Penn State University College of Medicine, Hershey, PA, 
(originally obtained from Dr. Stanley, University of Cambridge, UK). As a source of 
HPV-16 genomic DNA, W12 was also initiated from a low-grade cervical lesion 
histologically diagnosed as CIN I; with longer life span and known to contain 
approximately 100 copies of the HPV-16 genome, mainly in episomal form105. W12 
cell line, the non-tumorigenic cells were grown in tissue culture dishes (60- mm and 
100- mm) in E-Media (also a gift from Dr. Meyers) supplemented with 5% new born 
calf serum (NCS), nystatin (100,000U/ml) and epidermal growth factor (EGF) from 
treated mitomycin C, 2 mg/5ml (Roche Diagnostics Corporation, Indianapolis, IN)-
J2 feeder layers230 in Dulbecco’s medium Eagle with L-glutamine (Invitrogen) 
containing 10% NCS and gentamicin (Gibco, Invitrogen) and maintained at 370C 
with 5% CO2 and 95% humidity. The J2 mouse fibroblasts feeder cells previously 
grown in tissue culture dishes  (100- mm) were also from Dr. Meyers (originally 
obtained from Paul Lambert, Ph.D. of University of Wisconsin-Madison). Following 
treatment of J2 cells, they were washed three times in PBS before trypsinization. The 
fresh J-2 mitomycin C treated cells were added to the W12 cultures once at the 
beginning of culture and refed with the treated J2-feeders every 4-5 days thereafter 
until W12 cells are 70-80% confluent. 
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 The SiHa cell line purchased from American Type Culture Collection (ATCC 
# HTB-35; Manassas, VA) was used as a positive control. These cells contain one or 
two copies of integrated HPV -16 DNA173. Cell culture of SiHa cervix squamous 
carcinoma cells were maintained in DMEM (Mediatech, Inc. Manassas, VA) 
supplemented with 10% heat-inactivated Fetal bovine serum (FBS) (Mediatech, Inc. 
Manassas, VA), L-glutamine and PennStrep media and maintained at 370C with 5% 
CO2 and 95% humidity.  Cells were grown in cell culture flasks and refed at 48 hours 
with fresh SiHa medium and every 2-3 days thereafter until they become about 80% 
confluent.  
3.3.2. Treatment conditions  
Two groups of 70% confluent W12 cells were exposed to 0.01% N-9 
(Spectrum Chemical Manufacturing Corporation, New Brunswick, NJ) in 100 –mm 
plates at 370C for 10 min. N-9 was drained from both groups and the W12 cells were 
maintained in mitomycin C-treated J2 cells, a non-dividing fibroblast feeder layer 
providing both attachment and growth factors for epithelial cells. The epidermal 
growth factor increases W12 colony size in the presence of the feeder cell layer. After 
1 hr, the growth media were drained again to remove the diffused N-9 and re-fed 
with the mitomycin C-treated J2 feeder cells until confluent.  After washing the cells 
with PBS, the first survivors of N-9 treated W12 cells from group one were 
harvested. The other group of cells were subjected to uninterrupted passage into 
another two groups and maintained as previously indicated, treated with N-9 when 
confluent under the same conditions as above. The second treated survivors were 
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handled as the first survivors with continuous harvesting, passage and exposures to 
N-9 to generate increased strand breaks over extended period of population 
doublings in the W12. This repeated treatments with the 0.01% N-9 enhanced their 
selection. Untreated cells and SiHa cells were included as negative and positive 
controls respectively. N-9 constituted stock solutions were stored at 40C and used 
before seven days. Serial dilutions of N-9 stock in PBS were immediately prepared 
before every experiment. After harvesting, cells were subjected to DNA extractions.   
3.3.3. Hirt DNA preparation  
Confluent W12 cells were collected from the 60- mm plate and selective 
extraction of low-molecular weight (LMW) DNA was performed by following a 
modified Hirt protocol231,201,232,94. Briefly, after rinsing with cold PBS; the cells were 
lysed by adding 200 µL of Hirt solution [10 mM Tris, 10 mM EDTA (pH 7.5), 0.6% 
Sodium dodecyl sulfate (SDS)] and incubated at room temperature for 10 min. The 
plates were gently rocked for 2 min after precipitation with high salt in 100 µl of 5 M 
sodium chloride (NaCl). The viscous cell lysate was scraped from the plate with a 
cell scraper and transferred to a micro-centrifuge tube. Following addition of twice 
1.5 µL (3.0 µl) DNase-free RNase A (10 mg / ml) to final concentration of 50 µg/ml, 
the mixture was incubated overnight at 40C. After centrifugation at 14,000 rpm at 
4°C for 40 min, the compact pellet (containing the HMW DNA) was saved at -20°C 
and 1 µl of 20 mg / ml (final concentration of 25 µg / ml) PCR-grade proteinase K 
solution (Roche Diagnostics Corporation, Indianapolis, IN) containing 48.6 U/mg 
protein was added to the supernatant and incubated at 37°C for 1 hr. The aqueous 
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phase containing viral DNA was extracted twice with equal volumes of saturated 
phenol and once with chloroform/isoamyl alcohol (24:1) using standard 
protocols233,234. The DNA in the supernatant was precipitated with one tenth volume 
of 3M sodium acetate (NaOAc) and two volumes of 100% ethanol at -20°C overnight 
and centrifuged at 14,000 rpm for 20 min. The DNA pellet was washed with equal 
volume of 70% ethanol and centrifuged as previously for 5 min and dried. The pellet 
was re-dissolved in 160 µL of RNase, DNase and Protease Free molecular grade 
water. To ensure re-suspension, the DNA was first incubated overnight at 40C, then 
at 370C for 15 min prior to use for PCR analysis. DNA purity and quantity was 
determined using a DU800 Spectrophotometer (Beckman Coulter, Fullerton, CA). 
3.3.4. Total genomic DNA extraction 
W12-exposed N-9 cultures were harvested for preparation of high molecular 
weight DNA as described234,201,235. In brief, after washing the cells in 100- mm plate 
with cold PBS, they were trypsinized into 15 ml conical tube and centrifuged at 4000 
rpm for 5 min. Following removal of the supernatant, the pellet was re-suspend in 3 
ml of Hirt extraction buffer [400 mM NaCl, 10 mM Tris.Cl, pH 7.4; 10 mM EDTA 
(pH 7.5)]. After addition of twice 15 µL (30 µL) DNase-free RNase A (10 mg / mL) to 
final concentration of 50 µg/mL, 60 µL of 10% sodium dodecyl sulfate (SDS) was 
also added to final concentration of 0.2% and the mixture was rocked in a shaking 
incubator at 370C overnight. Then 7.5 µl proteinase K solution [(20 mg/mL), Roche 
Diagnostics Corporation, Indianapolis, IN] was added to final concentration of 50 
µg/ml and rocked again in the shaking incubator at 370C for extra 3 hours. The 
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DNA was sheared by passing through an 18 gauge needle ~ 10 times and the digest 
was de-proteinized twice by phenol-chloroform-isoamyl alcohol (25:24:1) extraction, 
followed by chloroform extraction, and the supernatant containing the DNA was 
recovered by ethanol precipitation and then air dried and re-suspended in 100 µl of 
RNase, DNase and Protease Free molecular grade water. The virus DNA was then 
subjected to PCR analysis. The purity and concentration of total DNA was 
determined by spectrophotometric measurement using DU800 Spectrophotometer 
(Beckman Coulter, Fullerton, CA).  
3.3.5. Sources of PCR primers 
The HPV-16 DNA primers and the Alu-PCR amplification primers as 
previously described236,237,238 used in the analyses are indicated in Table 3.9. Primers 
for the PCR were obtained from Integrated DNA Technologies (Coralville, IA). 
3.3.6. PCR analysis of Hirt DNA for HPV-16 E2 / E6  
Extra chromosomal (Low molecular weight) DNA from the cultured W12 
cells maintained episomally was used for the PCR analysis. Specific HPV-16 E2 and 
E6 primers were used as shown in Table 3.9. Each PCR reaction mixture of 50 µl 
contained 800 ng of template DNAs, 1X PCR buffer, 1.5 mM MgCl2, 200 µM of 
deoxynucleotide triphosphates (dNTPs), 0.4 µM of the oligonucleotide primer and 
0.25 µl of thermostable DNA Taq polymerase (Promega, Madisom, WI) at final 
concentration of 2.5 units.  
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Table 3.9: Polymerase Chain Reaction Primers for HPV-16 E2 / E6 and Alu 
sequence. 
Names of primers specific for HPV-16 E2 and E6 and separate Alu sequences and 
their corresponding nucleotide sequences and melting temperatures due to 
differences in G-C content are shown.  
The numbers represent the nucleotide numbers in the complete HPV-16 genome. 
 
 
Primer 
Description 
                               
 
Nucleotide sequence 
(5’               3’) 
 
≈ Melting 
Temperature 
(≈ Tm), 0C 
 
 
Interspersed repetitive (Alu) sequence 
 
Inter Alu-1 GGATTACAGGCATGAGCCA 58 
Inter Alu-2 ACCACTGCACTCCAGCCTG 62 
Inter Alu-3 TGGCTCACACCTGTAATCC 58 
 
HPV-16 
 
E2 Forward 3438CTTGGGCACCGAAGAAACAC3457 62 
E2 Reverse 3789 TTGGTCACGTTGCCATTCAC3769 60 
E6 Forward 26AAGGGCGTAACCGAAATCGGT46 64 
E6 Reverse 233CATATACCTCACGTCGCAG215 58 
 
 
 
 
 
The conditions for PCR analyses were as follows: Samples were subjected to an 
initial denaturation step (“hot start”) at 950C for 5 min to denature the double 
stranded DNA. The samples were then subjected to 30 cycles of amplification on an 
automated heating block, Applied Biosystems 2720 Thermal Cycler version 2.08 
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(Foster City, CA), each cycle consisting of denaturation at 950C for 1 min, primer 
annealing at 520C for 1 min and DNA synthesis by elongation in the presence of heat 
stable Taq DNA polymerase at 720C for 1 min per 1000 base pairs. Upon completion 
of the last cycle, the tubes were incubated at 720C for 10 min for final extension then 
cooled at 40C until processed. The tubes containing the amplified DNA may be 
stored in the -200C freezer for future use.  
3.3.7. DNA gel electrophoresis 
The PCR amplification products were separated by electrophoresis on a 1.0% 
agarose gel and visualized with ethidium bromide staining. Radiographic images 
were obtained by using FluoChem™ 8900 (Alpha Innotech, San Leandro, CA). 
3.3.8. Alu-PCR amplification of total DNA for HPV-16 genome 
Alu-PCR analysis for compound-treated W12 cells (four generations of 
continuous subcultures) containing HPV-16 DNA was used to detect integrated 
HPV DNA. Specific HPV-16 E2 primer and Alu sequence primers were used as 
listed in Table 3.1. PCR was carried out as previously described239,240,225,206. The PCR 
reaction was performed in a 50 µl volume with 150 ng of template DNA, 1X PCR 
buffer, 1.5 mM MgCl2, 0.2 mM of each dNTP, 0.5 µM of each primer and 2.5 units of 
Taq DNA polymerase ((Promega, Madison, WI). Pre-incubation PCR conditions 
were 950C for 5 min. Cycling conditions were 950C for 1 min, 520C for 1 min and 
720C for 1 min for a total of 30 cycles. Upon completion of the last cycle, the tubes 
were incubated for 720C for 10 min then held at 40C until processed. The amplified 
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products were visualized following electrophoresis with ethidium bromide staining. 
Radiographic images were obtained by using FluoChem™ 8900 (Alpha Innotech, 
San Leandro, CA). 
3.4. Results  
3.4.1. Validation of HPV-16 E2 / E6 in W12 by PCR 
To confirm that the cervical keratinocytes W12, contain mainly episomes 
following Hirt LMW DNA extraction; we detected HPV-16 E2 and E6 using PCR. 
In the verification of the PCR reaction to determine the HPV-16 DNA status in the 
W12 extracted DNA, that the desired band is amplified and also determining if there 
are other bands that may result non-specific annealing and amplification, following 
completion of the thermal cycler run, 10 µl of the PCR products were subjected to 
DNA electrophoresis. The Hirt supernatant method enhances DNA quality and 
yield. E2 was used to examine the virus episomal integration approach because 
following integration, the E2 ORF is interrupted209. This first stage of the PCR assay 
was designed to amplify HPV-16 genome in order to determine whether intact HPV-
16 genome is present in W12 cell line exhibiting typical keratinocyte morphology. 
Because our interest is on the episomes, we used the low molecular weight extracted 
DNA since Hirt supernatant enriches episomal DNA. Plasmid HPV-16 (pHPV-16) 
was used as positive control, mimicking HPV integration in vitro. To improve 
specificity, the thermocycler block was heated up to at least 800C before samples 
were put in. As shown in Figure 3.9, on a 1% TAE agarose gel HPV-16 E2 and E6 
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bands were 351-bp and 207-bp respectively from the PCR total reaction of 50 µl 
containing 800 ng of the template. Molecular marker sizes and HPV-16 E2 size were 
indicated. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
W12 extra-chromosomal DNA was amplified with HPV-16-specific E2 and E6 
primers as indicated in Table 3.9. E2 forward and reverse primers were used in lanes 
1-4, while E6 forward and reverse primers were used in lanes 5-7. 10 µl of the PCR 
products from reactions E2 and E6 containing 800 ng of template DNA in the gel 
after electrophoresis in a 1% TAE agarose gel, ethidium bromide staining, and UV 
fluorescence are shown in lanes 4 and 7 of the autoradiogram, respectively. 
Molecular sizes of 351-bp (E2) and 207-bp (E6) are indicated. HPV-16 plasmid (pEF 
399) DNA with backbone pUC19, lanes 2 and 6 as positive and lanes 1 and 5 as 
negative controls for E2 and E6 respectively and water, lane 3 as additional negative 
control. Arrowheads indicate the expected 351-bp and 207-bp HPV-16 DNA E2 and 
E6 respectively. Lanes M (marker), 100-bp DNA ladder also indicated. 
 
3.4.2. Detection of integrated HPV-16 DNA  
This performance using Alu-PCR was to examine whether the one to two 
copies of integrated HPV-16 DNA were detected by the Alu-primers (1, 2, 3) and E2 
 M         1             2          3             4            5           6             7            M 
 
351 bp 
 
207 bp 
Figure 24.1: Detection of intact presence of HPV-16 E2 and E6 by PCR 
in W12 cells. 
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primers of HPV-16. As a follow-up of the PCR reaction above, to test whether there 
could be integration, we decided to run controls with the three Alu primers using, 
SiHa cells containing the linearized HPV-16 DNA173 instead of the W12 cells as 
shown in Figure 3.2 on a 1% TAE agarose gel. Molecular marker sizes and episomal 
HPV-16 size were indicated. In this assay, because our interest is on the genomic 
DNA, we used the high molecular weight extracted DNA. All the three Alu primers 
against HPV-16 E2 primer showed smears.  Alu-2 showed an even smear and was 
therefore used in the actual experiment for the integrant detection. We were 
expected to see no HPV-16 E2 distinct band during integration in PCR products, 
hence the smear. 
3.4.3. Alu-PCR analysis of HPV-16 DNA during extended N-9 treatment of W12      
cells  
Having identified that the W12 cells have episomes and that the selected Alu 
primers could detect the integrated copy/copies of HPV-16 in SiHa cells, we 
proceeded to the second stage of the PCR assay, the Alu-PCR to find out if episomal 
copies of HPV-16 in W12 cells have integrated. Following extraction, to assess the 
HPV-16 DNA integration, we determined viral sequences in the host genome via 
PCR. Integrated Alu/HPV-16 PCR was performed to investigate the physical state of 
HPV-16 during 10 minutes 0.01% N-9 treatment and subsequent passage of W12. 
The rationale of passages in vitro was that integration of viral episomes is associated 
with the development of phenotypic and genomic abnormalities resembling those 
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observed in cervical neoplastic progression in vivo. Four generations of continuous 
subcultures of W12 N-9 treated cells were harvested and applied in the assay. 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
SiHa genomic DNA was amplified with HPV-16-specific E2 reverse primer and Alu-
1, -2, -3 primers as indicated in Table 3.9. 25 µl of the PCR products from reactions 
containing 400 ng as template DNA in the gel after electrophoresis in a 1% TAE 
agarose gel, ethidium bromide staining, and UV fluorescence are shown in lanes B, 
D and F of the autoradiogram representing Alu-1, Alu-2 and Alu-3 respectively 
against HPV-16 E2 reverse primer. HPV-16 DNA from SiHa cells, lane H as positive 
control (351 bp) and lanes A, C and E as negative controls for Alu-1, Alu-2 and Alu-3 
primers respectively and water, lane G as additional negative control. Lanes M 
(marker), 100-bp DNA ladder also indicated. 
 
 
 
The starting W12 cells contain only episomes105. In the Alu/HPV-16 PCR, the HPV-
16 specific primer was grounded in HPV DNA and the Alu primer was grounded in 
the cell DNA. In this assay also, because our interest is on the genomic DNA, we 
   M         A          B          C        D         E          F          G        H         M       
 
 
 
  351 bp 
   
 
 
 
 Figure 3.25: Detection of integrated HPV-16 DNA using Alu PCR in 
SiHa cells. 
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used the high molecular weight extracted DNA. We directly tested whether the 
DNA strand breaks induced by treated W12 cells with the DNA-damaging agent N-
9 may facilitate HPV DNA integration into the host DNA. We were expected to see 
no E2 band during integration in PCR products of N-9 treated cells verses untreated 
cells. Thus the Alu-2 showed a smear as illustrated in Figure 3.3. 
 
 
 
 
 
 
 
Figure 3.26: Detection of integrated HPV-16 DNA using Alu PCR in W12 cells. 
W12 cultures (four generations) treated with 0.01% N-9 for 10 minutes genomic 
DNA was amplified with HPV-16-specific E2 reverse primer and Alu-2 primer as 
indicated in Table 3.9. 25 µl of the PCR products from reactions containing 400 ng as 
template DNA after electrophoresis in a 1% agarose gel, ethidium bromide staining, 
and UV fluorescence are shown in lanes D, E, F, G and H of the autoradiogram 
representing only ten minutes treatment, first, second, third and fourth generations 
respectively against HPV-16 E2 reverse primer. HPV-16 DNA from SiHa cells 
(different batches), lanes B and I as positive controls and lanes A (water) and C 
(untreated cells) as negative controls for Alu-2 primer. Lane M (marker), 100-bp 
DNA ladder also indicated. 
 
 
       M           A          B          C         D           E           F            G        H           I        
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3.5. Discussion 
The integration of the HPV-16 DNA is an initial and significant event in the 
progression from pre-invasive to invasive cervical cancer199. This insertion of foreign 
DNA into the host genome may be another consequence of genetic instability 
induced by HPV-16 E6 or E7 expression. Although integration is a key event in the 
development of most cervical cancers, other subsequent events enhancing selection 
of integrants are required for progression of cervical malignancy. During 
deregulated viral oncogene expression and host genomic mutation, HPV-16 
genomes integrate into host DNA. Such host cells have selective growth 
advantage121. Integration of human papillomaviral DNA correlates with increased 
viral gene expression and cellular growth advantage. These observations are 
consistent with the hypothesis that integration provides a selective advantage to 
cervical epithelial precursors of cervical carcinoma212.   
 Expression of E6 and E7 proteins thus enhances their selective growth 
advantage and therefore increases the frequency of foreign DNA integration into the 
host genome. Because ‘high-risk’ E2 from episomes down-regulates these high-risk 
HPV oncogenes, the integration of viral genomes relieves these repressive activities 
of E2 on E6/E7 transcription and allows for increased expression of these viral 
oncogenes. 
HPV infection can lead to integration of the episomal form of the viral 
genome into the host genomic DNA, however the significance of integration to 
disease progression is not well understood. In a study, HPV-16 DNA was not 
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present in the integrated form in almost all tumors, signifying that integration and 
consequent inactivation of the transcriptional regulator, E2, are not essential steps 
for the development of HPV-16 associated carcinoma. In this manner, the behavior 
of HPV-16 associated tumors is different from HPV-18, -31, and -35 associated 
tumors, where the viral DNA is always present in the integrated form203. Thus, in 
advanced cervical intraepithelial neoplasia lesions, a subset of lesions can be 
identified in which the viral genome is integrated and there is a greater risk of 
malignant progression.  
The W12 cell line is a good model for study of the HPV-16 life cycle because 
the cells contain many episomal copies of the HPV-16 genome and can be induced to 
differentiate in monolayer culture to express markers of epithelial differentiation 
and virus late proteins212. The W12 cells thus maintain genome episomally241. 
During the use of the HPV-16 plasmid (pEF 399) DNA with backbone pUC19 as 
positive control in the detection of intact presence of HPV-16 E2 and E6 by PCR in 
W12 cells, the signal was very strong overshadowing that of E2 and E6. To overcome 
this obstacle, we titrated the plasmid and use appropriate quantity in the 50 µl total 
volume of PCR reaction. 
 Following N-9 treatment of W12 cells with continuous subcultures, we found 
that W12 cell line expressing HPV-16 E6 and E7 oncoproteins were proned to 
integrate HPV-16 DNA into the cellular DNA242. Integration was indicated with a 
smear, pronounced in the first generation and fourth generations of subcultures 
after compound treatment. Loss of p53 function through interaction with E6 protein 
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of high-risk HPV types is an essential event regarding cervical carcinoma 
development131.  
 In conclusion, even though there is no epidemiological data linking potential 
DNA damage by spermicides/microbicides such as N-9 and cervical cancer 
progression as this study is a new concept; integrated Alu/HPV-16 PCR for 
detection of integrated HPV-16 DNA in W12 cells following passages in vitro can 
help to analyze the physical status of HPV-16 DNA. However, to fully determine the 
physical state of HPV-16 DNA in W12 cells following N-9 treatment using 
integrated Alu/HPV-16 PCR, further studies will be needed. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 120 
4. OVERALL DISCUSSION AND FUTURE DIRECTIONS 
 
The focus of this dissertation has been the safety assessment of the “new 
hope” of human immunodeficiency type 1 (HIV-1) and other sexually transmitted 
diseases (STD) pathogens referred to as topical microbicides following human 
papillomavirus (HPV) infection and repeated use of these compounds. More than 
90% of cervical cancers are due to HPV infection85,243. Specifically, sodium dodecyl 
sulfate (SDS); the alkyl sulfate was examined for its low toxicity profile relative to 
Nonoxynol-9 (N-9) as a potential spermicide replacement for N-9 in condoms. Also 
examined was the role of the N-9 associated DNA damage on the possible increase 
risk of high-risk (HR)-HPV DNA integration into the host DNA that might enhance 
the probability of cervical carcinoma progression. This concluding discussion 
includes the following: The need for topical microbicides as STD/HIV prevention 
options, the dissertation rationale, basic conclusions resulting from the studies and 
the importance of such studies. Also for each of the studies conducted, the urgent 
questions to be asked and future experimentation to address the gaps in knowledge 
and interventions will be discussed.    
Control and prevention of HIV-1 and other STD is a global priority due to the 
associated morbidity and mortality2,1. The global HIV-1 and other STD epidemic 
have had a particular severe impact on women. Especially, in countries with the 
highest global HIV-1 seroprevalence rates, up to 60% of HIV-1-infected adults are 
women184. This has gone up from 25% in 1992. These UNAIDS figures indicate that 
women are the most vulnerable population of HIV because of their low social status.  
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It will prove difficult accomplishing the millennium development goals such as 
promotion of gender equality and empowerment of women, improve maternal 
health and fight HIV/AIDS should the present trend of increasing infection in 
women continues. Women are also biologically more susceptible than men to many 
STD including HIV. Therefore, HIV infection in women is becoming more intense 
than in men. Prevention technologies are a vital weapon in the battle against HIV-1 
and the pathogens causing this epidemic. 
Approaches to HIV-1 and other STD prevention include new products and 
strategies among which are education and behavior modification, condoms, and 
other barrier methods such as diaphragms, treatment/prevention of drug/alcohol 
abuse, usage of clean syringes (i.e. needle exchange programs), interruption of 
mother-to-child transmission of HIV-1 and pre-exposure prophylaxis (PrEP), topical 
microbicides, non-condom prevention of HIV-1 and other STD, male circumcision 
and vaccination244,245,246,247. Although traditional technologies such as condoms are 
effective against these sexually transmitted infections, for many women they are not 
a viable option. For some women, social pressures and the need to negotiate with 
their male partners can make condom use a difficult proposition12,186,2,189,8,187,188. 
Condom use in such spouses remains low. Thus for couples who do not use condom 
consistently and correctly, safe and effective microbicides would offer an alternative 
method of protection. Moreover, such products have the tremendous potential for a 
woman-controlled defense against infection and disease. Microbicides may also 
offer significant health benefits by preventing transmission and acquisition of STD 
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other than HIV-1, and potentially offering another form of contraceptive. Despite the 
set backs due to the failure of trials of N-9, Cellulose sulphate, and ineffectiveness of 
Carragurad, the development of microbicides remains a priority because they have 
merely enhanced the resolve of the research community and agencies to find new 
solutions. Also some of the major preventive measures such as circumcision 
protecting men do not protect women. Thus, female-initiated HIV-1 prevention 
methods are needed without delay.  
Among the current prevention technologies, to design and develop these 
topical microbicides; areas to explore are safety (increased susceptibility?) 
behavioral aspects (e.g. adherence, acceptability), combination microbicides [similar 
to Highly active anti-retroviral therapy (HAART)] and develop long acting methods 
of delivery. 
The thesis project rationale was therefore three-fold. These are: 
• Generate data in support of recommending alternative contraceptives, e.g. 
SDS to N-9 spermicides. 
• Design and develop topical spermicides and microbicides to empower 
women. 
• Examine the relationship between potential DNA damage by spermicides 
and microbicides and cervical cancer progression. 
The project rationale was based on the following reasons: 
• N-9 has been shown to be an ineffective microbicide and also increases 
risk of HIV-1 and other STD pathogens transmission and acquisition38,40. 
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• There are no commercial alternatives to N-9 and other classes of 
microbicides. 
• Microbicide research and development has been considered as an 
“orphan” medication and therefore, the big pharma are not involved. 
• Recent closure of phase 3 clinical trials of potential microbicides 
(Carraguard® and Cellulose sulfate) due to inherent safety 
concerns146,147,148. 
The first study focused solely on the safety of a candidate microbicide in HIV-
1 and other STD is in chapter 2. It is likely that vaginal microbicides will be used by 
HIV-1 and other STD pathogens infected women who may or may not be aware of 
their sero-status, and since microbicides interact with cell membranes, we believe 
that such compounds could cause DNA damage. A comparison of the topical 
spermicide and microbicide demonstrated that for the alkaline version of the comet 
assay, based on fold determinations; on increasing order, SDS is less damaging 
relative to N-9, although both compounds induced some DNA damage.  Below are 
the summaries made in reaching the above general conclusion. 
• N-9 causes relatively more DNA damage than SDS in HeLa cells as evidenced 
by the comet assay. 
• N-9 and SDS caused DNA damage after 10 min of treatment at 0.01%, 
o N-9 > SDS.  
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• In comparing the same percent concentration (0.01%) to the molarity 
equivalent of N-9 (0.162 mM), N-9 still caused relatively more damage than 
SDS in HeLa cells.  
• N-9 induces relatively more DNA damage at 10 minutes in HeLa cells than in 
primary keratinocytes, perhaps due to different levels of p53 in both cells. 
• DNA damage was partially repaired after 10 min at 0.01%, N-9 < SDS. 
• After 2 hr of recovery, SDS probably repaired damaged cells relatively better 
than N-9. Though 100% repair not achieved, we are certain that recovery has 
occurred. 
• HeLa cells are suitable substrate for DNA damage assessment using the 
cometAssay™. 
• DNA repair can be monitored by incubating cells after treatment with 
damaging agent and measuring the damage remaining at intervals. 
• Measuring DNA damage and repair is a novel way to evaluate 
spermicides/microbicides candidates. 
• Evaluating formulations under the same testing conditions can help to 
distinguish between potential compounds likely to show promise as safe 
microbicides. 
In summary, this study demonstrated that, 
• SDS is a suitable candidate for continued development as a female controlled 
topical (vaginal) spermicide/microbicide. 
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• Enabled us to add our voice to the growing list of the need to replace N-9 in 
condoms with an acceptable, appropriate and less damaging agents.  
Thus, SDS, a broad-spectrum microbicide has activity against HIV-1, HPV, 
HSV-2, Chlamydia trachomatis and Neisseria gonorrheae in vitro; biodegradable and on 
FDA’s GRAS list may prove safer than N-9 as a microbicide/spermicide coating of 
devices (to substitute N-9 in condoms) and or as a female controlled microbicide.. 
The demonstration of SDS safety in vitro is important in planning for its assessment 
in clinical trials.  This assessment using DNA damaging levels is a new comparator 
for microbicides safety.  
Evaluation of DNA damage has a novel way to determine the safety of 
candidate spermicides/microbicides. Large-scale microbicide trials such as 
Carraguard®, Savvy™ and Cellulose sulfate have had to be halted over safety 
concerns. These well publicized patterns of failures risks losing the confidence of the 
public. Furthermore, these set backs have only augmented the resolve of the 
research community and agencies to find new solutions. Microbicides are a real 
possibility that have the capacity to save millions of lives. Research, development 
and advocacy must be scaled-up for the realization of this hope until satisfactory 
microbicides are licensed. This would hopefully make HIV-1/AIDS and other STD 
prevention research more actively and carefully planned. For review see the 2007 IAS 
conference Abstract Numbers: WESS302 and TUPEC008. www.iasociety.org.    
The second study in chapter 3 focused on HPV integration studies. As a new 
concept, there is no epidemiological data linking potential DNA damage by 
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spermicides/microbicides and cervical cancer progression. Therefore, here we 
examined whether the DNA strand breaks induced by treated W12 cells with the 
DNA-damaging agent N-9 (in chapter 2) may facilitate HPV DNA integration into 
host DNA. Although HPV-16 integration is a key event in the development of most 
cervical cancers, other subsequent events enhancing selection of integrants are 
required for progression of cervical malignancy. The results of this study 
demonstrate that in the analysis of the physical state of HPV-16 DNA in W12 cells 
following N-9 treatment, integrated HPV-16 DNA was detected using integrated 
Alu/HPV-16 PCR, though for complete determination, additional studies are 
required. Integration as rare event is not detected in all invasive cervical cancer 
cases248,249. Below are the summaries made in reaching the above general conclusion. 
 
• N-9 treatment associated with DNA damage may increase HPV DNA 
integration into the host genome and therefore increase the risk of cervical 
cancer.  
• Detected presence of episomal HPV-16 DNA as a positive control in W12 cell 
culture by PCR analysis. 
• In using Alu-primers and E2 primers of HPV-16, integrated HPV-16 DNA 
was detected by the Alu-PCR. 
• Detected integrated HPV-16 DNA in W12 cells using integrated Alu /HPV-16 
PCR. 
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W12 cell line expressing HPV-16 E6 and E7 oncoproteins are more prone to 
integrate HPV-16 DNA than control cells or cells expressing HPV-6 and -11 E6 or E7. 
Moreover, HPV-6 or -11 bestows little or no selective growth advantage to affected 
cells. Thus, integration of HPV-6 and -11 is only rarely seen in primary tumors242. 
Expression of HPV-16 E6 and E7 transforming oncogenes has been found in cervical 
cancer cell lines and cancer biopsy specimens, and the two proteins play roles in 
malignant transformations. They are independently able to immortalize various 
human cell types in tissue culture, when they are coexpressed, their efficiency is 
elevated214. Integration provides a selective advantage to cervical epithelial 
precursors of cervical carcinoma212.  In a study, HPV16 DNA was not present in the 
integrated form in almost all tumors, signifying that integration and consequent 
inactivation of the transcriptional regulator, E2, are not essential steps for the 
development of HPV-16 associated carcinoma. In this manner, the behavior of HPV-
16 associated tumors is different from HPV-18, -31, and -35 associated tumors, 
where the viral DNA is always present in the integrated form203.  
In the induction of DNA damage as a measure of the safety parameters for 
microbicide candidates, comet assay is used for such measure of DNA 
fragmentation levels. The alkaline comet assay is a sensitive method for the 
detection of DNA strand break damage in cells. It is the method of choice for 
measuring DNA damage, of various sorts, in human cells such as lymphocytes. 
Other areas of importance include hazard identification and risk assessment of 
environmental and occupational exposure, diseases linked with oxidative stress (e.g. 
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diabetes and cardiovascular disease), nutrition, monitoring the effectiveness of 
medical treatment and investigating individual variation in response to DNA 
damage that may reflect genetic or environmental influences.  
  Microbicide development became a priority when the available HIV 
prevention tools in the absence of HIV vaccine were inadequate, though significant 
progress in HIV transmission prevention was ongoing12.  The priority of the 
microbicides field is proof of concept, validated safety and substituted effectiveness 
endpoints and true placebos.  
Large-scale phase 3 effectiveness microbicide trials were recently stopped 
early in Nigeria and Ghana due to disappointing data. In the case of cellulose sulfate 
(CS), the microbicide product failed to produce the desired effect as it did not 
prevent HIV-1 infection and may have increased the risk of HIV-1 transmission and 
acquisition. However, the trial itself was not a total failure since it generated a clear 
result, although it was not the anticipated result. For review see ClinicalTrials.gov 
number NCT00120770. Moreover, the CS and Savvy™ trials were halted because the 
overall incidence of HIV-1 was lower than expected and investigators did not 
anticipate being able to detect any treatment effect (Abstract TUPEC008, 2007 IAS 
conference on HIV pathogenesis, Treatment and Prevention, www.iasociety.org). 
The negative effects of these terminated trials comprised delay in the development 
of new HIV-prevention interventions, wastage of limited resources, and decreased 
trust between research teams and trial communities. Additional testing of candidate 
products using various approaches, with different mechanisms of action is vital; 
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maximizing efficiency and minimizing costs with multiple products concurrent 
testing250,251,252,253. 
Other microbicide trials are therefore ongoing or planned. Clinical testing of 
microbicides ought to be thorough and ethical254. Should testing reveals limits on 
safety of products under certain conditions, such conditions must be clearly 
restricted on the product labeling when the public have access. In assuring quality 
trials, cultural, language, educational, and social status differences between trial 
officials and the participants must all be considered in achieving fully informed 
consent. A phase 3 clinical trials is difficult to conduct under most circumstance. 
Microbicide development has challenges, as this is a pivotal moment. Among these 
obstacles are lack of biological markers of activity or protection, no true placebos 
and ethical need to promote condoms making effectiveness trials large and difficult. 
Besides, these compounds may be toxic and irritating causing inflammatory 
processes, which may cause DNA damage. Such inflammation might increase risk of 
HIV-1 transmission through the lymphocytes recruitment as target cells. Microbicide 
trial’s is more challenging since many trials are conducted in developing countries 
where infrastructure may not exist or is untested. Thus, microbicide trials should be 
designed carefully and be ethically sound254,251. 
 Scientific advances are providing better understanding of STD and the 
connections bridging basic and clinical research give cause for optimism for an 
inexpensive, broadly acting and highly effective microbicide.  
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Mutagenic agents from the environment and cellular metabolism continually 
alter cellular DNA. This DNA damage, and the resulting mutation, plays a vital role 
in many phenomena in biology, notably evolution, antibiotic resistance in bacteria, 
toxicity, initiation of cancerous cells in animals and treatments for cancer. Other 
possible effects include HPV integration and increase of HIV-1 targets for 
transmission. DNA repair is the first line of defense against mutations that cause 
cancer. Double-strand breaks (DBSs) are possibly dangerous for organisms due to 
the inappropriate recombination of the free ends with other parts of the genome 
causing substantial damage. Eukaryotic cells sense and with efforts to repair such 
breaks quickly, via recruitment of DNA repair enzymes to the damage sites, forming 
nuclear repair foci. The monitoring of DNA repair in human cells in this way 
(assessed by comet assay) is a novelty. Poor DNA damage repair may result in 
premature aging, increased to carcinogens and therefore risk to cancer. 
As the most common STD globally, HPV is part of, and occurring within a 
much larger STD epidemic. It is the number one cause of female cancer mortality in 
developing world and the principal cancer of women in most developing countries. 
The most efficient method of combating cervical cancer is to prevent infection of 
mucosal epithelial surfaces by HPV. Vaccination against such infections could 
considerably decrease incidence of cervical cancer. With an estimated 500,000 new 
cases of cervical cancer and 250,000 deaths per year worldwide, Gardasil®, the HPV 
vaccine would have a global public health benefit particularly in women of 
developing settings, though it does not cover many types. It is equally important as 
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a safe and effective HIV Vaccine, critical to the effective control of HIV-1 globally. 
HIV vaccine is an important and difficult scientific challenge in AIDS prevention 
research. 
As a consequence of our previous finding via the comet assay that 0.01% N-9 
treatment is associated with elevated DNA damage we decided to investigate 
whether this phenomenon may increase HPV DNA integration into host genome 
and therefore facilitates an increased risk of cervical cancer.  
Episomal integration is a critical event in HPV-related oncogenesis. The 
model system used for integration studies was W12 cell line. W12 was generated 
from a cervical low-grade squamous intraepithelial lesion ‘naturally’ infected with 
HPV-16, at low passage containing approximately 100 HPV-16 episomes per cell174. 
HPV oncogenes that are expressed in these cells are involved in their transformation 
and immortalization, and are required for the progression towards malignancy. 
Though plays a major role in invasive carcinoma progression, HPV infection 
with high risk types is necessary, but insufficient cause85,214. Viral integration, an 
extra-chromosomal recombination event also plays pivotal role in the progression of 
intraepithelial to invasive cancers in majority of cases199.  HPV lesion progression 
and integration may be altered by secondary factors including other STD, such as 
HSV-2, Chlamydia and Inflammatory events. Other factors are mutagens or 
carcinogens. These work at the DNA level and are potential initiators for cancer 
formation. Examples of mutagens are chemicals, radiation and viruses. 
Epidemiological studies indicate that women with HR-HPV such as HPV-16 and 
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HSV-2 co-infection have higher risk of developing cervical carcinoma255,256,257,258. 
The actual interaction, however between HPV and HSV-2 during cervical cancer 
progression remains unclear.      
DNA damage checkpoint genes, such as p53, are often mutated in human 
cancer, but the selective pressure for their inactivation is not well understood. 
Persistent infection with high-risk human papillomavirus (HPV) has been linked to 
cervical carcinoma. Integration of viral DNA into host cell DNA is essential for this 
cancer development, promoting disruption of the HPV E2 gene, thus leading to 
unregulated increases in E6 and E7 proteins and inactivating the products of p53 
and Rb tumor suppressor genes131,127. Thus, the normal functions of pRB and p53 
proteins are abolished in human cervical cancer, either by mutation of the genes 
themselves or as a consequence of specific interaction of these proteins with the E6 
and E7 oncoproteins128. 
There are no all-inclusive cancer-control programs in Africa and other 
developing settings and provision of radiotherapy, chemotherapy, and palliation is 
insufficient. Certain cost-effective strategies for instance tobacco control, provision 
of antiretroviral therapy, and malarial control and screening efforts, can cause 
considerable reductions in the burden of some of these cancers. Vaccinations against 
oncogenic humanpapilloma viruses can be a viable venture, but they are expensive 
and does not cover all strains of the virus259,260,261,262,263,264. 
Though, Carraguard® has failed, further studies are warranted for the “proof 
of concept.” Carragurd® need to be compared to N-9 and access its ability to cause 
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DNA damage and also inactivation of HIV-1 and other STD pathogens. A complete 
comparison of N-9 with other spermicides/microbicides to see if they also induce 
DNA damage is indicated. To be ideal, these potential topical microbicides must 
have broader activity and lower toxicity. Should microbicides become available, 
they could have an enormous public health benefit. 
In learning from concept failures, although potential microbicide trials have 
failed recently, more research is needed till safe product is obtained. 
Although the knowledge of cervical cancer globally is improving, better 
surveillance of cancer incidence, mortality, and prevalence of risk factors is urgently 
needed to monitor the development of the cancer epidemic, formulate appropriate 
cancer-control strategies, and assess the outcomes of these strategies. Given the 
mandatory role of HPV infection in the development of cervical carcinoma, 
paramount strategies for prevention and treatment require a better understanding of 
HPV biology. In particular, preventive vaccines with broader activity but also HPV-
targeted therapy warrant further investigation. 
When standardized and validated, addressing the many confounding factors 
mentioned above, the comet assay could provide invaluable information and be a 
promising new tool for topical spermicides/microbicides safety studies. 
1. Vital questions to be addressed: 
 Despite the fact that some studies have been done towards understanding 
microbicide safety measurement, the significance and detection of integration, more 
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experimental questions have to be addressed.  Below are the vital questions arising 
from my research that should be addressed:  
a. Does DNA damage and recovery facilitate the integration of HR-HPV 
genome into the host genome? 
b. Do chemical agents known to cause DNA damage promote this integration of 
HPV DNA? 
c. Does DNA damage cause cancer? 
d. Are there specific and intracellular factors that could sustain and prevent host 
cells from invading viruses’ attack? 
e. Can the presence of homologous recombination from RecA family of ATPases 
repair fragmentation such as double-strand breaks and inter-strand 
crosslinks?  
      f.   Is the comet assay data reproducible between individual users and 
            laboratories? 
2. Future work to address and understand HPV biology and development of   
cervical cancer: 
 To effectively address questions (a), (b) and (c) above, HPV-type-specific PCR 
to be performed with the use of HPV-type specific primer. Information obtained 
from this study will further help assess the risk associated with the repeated usage 
of chemicals with high toxicity levels either for prevention of sexual transmission or 
contraception. For, DNA damage may increase the risk of integration. Moreover, 
since integration of high risk HPV DNA plays a key event in cervical carcinogenesis; 
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such knowledge may be translated into the clinic to allow the prevention, screening 
and treatment of cervical cancer. 
 In order to address question (d), further work is expected to investigate the 
APOBEC family of cytidine deaminases activity on mounting mutations. These 
enzymes may mutate nuclear DNA and act against sexual pathogens such as HIV-1 
and HPV. For review, seeVartanian265. 
Addressing question (e) is essential in order to maintain genomic integrity as 
defects seen in recombination-mediated repair are linked with cancer. For review 
see Khanna266 and Chen267.   
The supplementary information provided by these future studies can enhance our 
better understanding of cervical cancer progression to the disease state and also 
combat HIV-1 and other sexually transmitted pathogens.  
A major interest in comet assay is to make the assay as reproducible as 
possible. Addressing question (f) may involve issues of good study design, 
confounding factors and the consideration of the variation in assay methodology. 
The incorporation of standard cells into the slides during experimental design to 
serve as additional controls to standardize and compare the technique, though the 
hydrogen peroxide inclusion provided some calibration of the DNA damage will all 
be helpful so that inter-laboratory comparisons will be achievable. For review of the 
control cells, see Trevigen Catalog # 4256-010-CC (CometAssay™ Control Cells). 
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Given that the comet assay shortcomings are well addressed, the method will 
be a good addition to the currently existing tests for topical microbicides safety 
studies with the possible development of SDS as a women-controlled microbicide. 
Female-controlled methods of STD/HIV prevention are urgently needed. 
Though, DNA integration studies are a technically challenging area of 
research but it has great potential for insights into the mechanisms of DNA repair 
and also the pathways of tumor progression. Additional clarification will be 
necessary in the mechanism of Alu integration into the human DNA268. Moreover, to 
fully determine the physical state of HPV-16 DNA in W12 cells following N-9 
treatment using integrated Alu/HPV-16 PCR further studies are required. 
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APPENDIX A: ABBREVIATIONS 
 
 
 
 
%  Percent 
α  Alpha 
β  Beta 
γ  Gamma 
µg  Microgram 
µl  Microliter 
µM  Micromolar 
0C  Degree celcius 
AIDS  Acquired immunodeficiency syndrome 
ATCC  American type culture collection 
bp  Base pair 
CDC  Centers for Disease Control and Prevention 
CIN  Cervical intraepithelial neoplasia 
CMC  Critical micelle concentration 
DMEM Dulbecco’s minimal essential medium 
DNA  Deoxyribonucleic acid 
DNase Deoxyribonuclease 
dNTP  Deoxynucleotide triphosphate 
DSBs  Double strand breaks 
FBS  Fetal bovine serum 
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FDA  Food and Drug Administration 
g  gram 
H2O2  Hydrogen peroxide 
HAART Highly active anti-retroviral therapy 
HIV-1  Human immunodeficiency virus type 1 
HPV  Human papillomavirus 
hr  Hour 
HR-HPV High-risk human papillomavirus 
HSV  Herpes simplex virus 
HSV-2  Herpes simplex virus type 2 
kb  Kilobase 
KBM-2 Clonetics® Keratinocyte Basal Medium-2 
kD  Kilodalton 
LCR  Long control region 
M  Molar 
mg  Milligram 
min  Minute 
ml  Milliliter 
mm  Millimeter 
mM  millimolar 
N-9  Nonoxynol-9 
NaCl  Sodium chloride 
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NCR  Non-coding region 
NCS  Neonatal calf serum 
ng  Nanogram 
NHEK Normal human epidermal keratinocytes 
nt  Nucleotide 
ORF  Open reading frames 
p53  Protein 53 
PBS  Phosphate buffered saline 
PCR  Polymerase chain reaction 
pRb  Retinoblastoma tumor suppressor protein 
ROS  Reactive oxygen species 
SCGE  Single-Cell-DNA Gel Electrophoresis 
SDS  Sodium dodecyl sulfate 
SEM  Standard error mean 
SSBs  Single strand break 
T1/2  Half time 
U.S.  United States 
UNAIDS Joint United Nations Program on HIV/AIDS 
WHO  World Health Organization
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